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PREFACE 
 
 Protein kinases function to transduce the countless number of signals that allow a 
cell to grow and adapt to its environment.  A significant number of protein kinases 
require assistance in being folded and converted into functional signal transducers from 
nascent polypeptides or in maintaining their functional conformation once folded. This 
assistance is provided by the molecular chaperone Hsp90 and its cohort Cdc37 which 
together function to fold protein kinases through a series of direct interactions.  A 
dynamic process which remains poorly understood.    
 In this work the interactions of three unique protein kinases with Hsp90 and 
Cdc37 were studied.  Lck, a Src-family tyrosine kinase, which is widely known to 
interact with Hsp90 and Cdc37.  Cdk2, a cyclin-dependent protein kinase, found to 
genetically although not physically interact with Hsp90 and Cdc37.  And JNK1α1, a 
stress activated protein kinase, which has shown not to interact with either Hsp90 or 
Cdc37.  To study these three kinases deletion mutagenesis and co-immunoabsorption 
techniques were primarily used to determine the molecular interactions of endogenous 
Hsp90 and Cdc37 with each newly synthesized protein kinase construct.  The results of 
this work indicate that: (i) Hsp90 interacts with structural motifs found in both the N-
terminal and C-terminal lobes protein kinases; (ii) Cdc37 interacts exclusively with N-
terminal lobe of protein kinases; (iii) depending on the kinase the presence of different 
structural motifs within the N-terminal lobe are required for Cdc37 interaction; and (iv) 
 iv
the minimum protein kinase structure required for high affinity salt stable Hsp90 and 
Cdc37 interaction is the N-terminal lobe through the stabilized αE-helix in the C-terminal 
lobe.  In turn, these findings provide insight into how Hsp90 and Cdc37 recognize, bind 
and fold client protein kinases. In addition, these findings provide clues to the 
evolutionary relationship between the Hsp90 chaperone machine and protein kinases. 
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would like to thank the following: Dr. Robert L. Matts for his relentless imagination, 
optimism, and patience.  Dr. Steven D. Hartson for his grounded and steadfast approach 
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Shao, Dr. Bo-Geon Yun, Dr. Bradley T. Scroggins, Jessica Matts, Yanwen Guo, Dr. 
Sheri Uma, Angela Irwin, and Wenjun Huang for their insightful and sometimes 
entertaining contributions.  Janet Rogers, SueAnn Hudiburg and Kate Cooley for their 
precision work in the core facility. My roommates James McDoulett and Crystal Power 
for giving me a place to live.  My friend Audrey Vecoven just because. My committee 
Dr. Richard C. Essenberg, Dr. Jose L. Soulages, Dr. Michael Massiah, and Dr. Robert 
Burnap.  My father and step-mother Dan and Kristi Prince for their support.  My caring 
sister Jessica Prince.  My brother Michael Prince for his confidence and encouragement.  
My grandmother Mary Lee Ruther for believing in me.  And most of all, I would like to 
dedicate this work and what ever may come of it to my late mother Suzanne I. Prince, 
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NOMENCLATURE 
 
 
17-AAG                                     17-allylamino-17-demethoxygeldanamycin 
ADP                                           adenosine diphosphate 
Aha I                                          activator of Hsp90 ATPase activity  
Akt 1                                          also known as PKB (protein kinase B) 
APH(3’)-IIIa                             aminoglycoside phosphotransferase 
ATP                                           adenosine triphosphate  
AU5-tag                                     peptide-TDFYLK 
Bag                                            Bcl-2 (B-cell lymphoma gene 2) associated gene product 
BLM                                          Cdc37 Bag-like motif 
CAK                                          Cdk activating kinase 
CD                                             Hsp90 C-terminal Domain 
Cdc                                           cell cycle dependent component 
Cdk                                           cyclin dependent kinase 
CHaK                                        transient receptor potentinal channel kinase 
CITD                                         C-terminal inhibitory tail domain 
CKII                                          casein kinase II 
CL                                             protein kinase C-terminal lobe 
Csk                                            c-Src kinase 
CSM                                          protein kinase non-catalytic C-terminal structural motif 
DMSO                                      dimethyl sulfoxide 
ErbB2                                       epidermal growth factor receptor B2 
Fkbp                                          FK506 binding protein 
Flag-tag                                     pepetide-DYKDDDDK 
GA                                            geldanamycin 
GHKL                                      DNA gyrase histidine kinase ligase protein family 
GR                                            glucocorticoid receptor 
Grp                                           glucose-regulated protein 
Harc                                          Hsp90-associating relative of Cdc37 
HBD                                          Cdc37 Hsp90 binding domain 
Hck                                           hemopoietic cell kinase 
Hip                                            Hsp70 interacting protein 
His-tag                                      peptide-HHHHHH 
Hop                                           Hsp70/Hsp90 organizing protein 
HRI                                           heme-regulated inhibitor of protein synthesis eIF2α kinase 
Hsc                                            heat shock cognate protein 
Hsp                                            heat shock protein 
HtpG                                          high temperature protein G 
 xiii
JNK                                           c-Jun N-terminal kinase 
KBD                                          Cdc37 kinase binding domain 
LBD                                          ligand binding domain 
Lck                                            lymphoid cell kinase 
LD                                             Hsp90 linker domain 
MAPK                                       mitogen activated protein kinase 
MD                                            Hsp90 middle domain                
NAD                                          Hsp90 N-terminal ATPase domain 
NCSM                                       protein kinase non-catalytic structural motifs 
NDM                                         NAD dimerization motif 
NL                                              protein kinase N-terminal lobe 
NLS                                           nuclear localization signal 
NSM                                           protein kinase non-catalytic N-terminal structural motif 
p23                                             23 kDa protein 
PDB                                           Protein Database www.rcsb.org 
PDK1                                         phosphoinositide-dependent kinase 
PP5                                             protein phosphatase 5 
PSTK                                         serine/threonine protein kinase 
PYK                                           tyrosine protein kinase 
Raf1                                            Ras activated factor kinase 
Rio2                                           ribosome processing kinase 2 
SAPK                                         stress activated protein kinase 
SH2                                            Src-homology domain 2 
SH3                                            Src-homology domain 3 
SHR                                            steroid hormone receptor 
Src                                              rous sarcoma oncogene protein kinase 
TnT                                            coupled transcription and translation  
TPR                                            tetratricopeptide repeat 
Trap1                                          type-1 tumor necrosis factor receptor associated protein 
TTC4                                          tetratricopeptide repeat containing protein 4 
TRiC                                          tailless complex polypeptide 1 (TCP-1) ring complex 
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CHAPTER I 
Introduction and Background 
Proteins are the molecular machines that give all biological entities the ability to 
exist and adapt effectively to their environment.  The central process in biology is the 
conversion of information encoded by genetic material into macromolecular units capable 
of functioning as biological machines.  Therefore, the synthesis of a protein can simply 
be described as the translation of one linear polymer composed of four different nucleic 
acid bases into another linear polymer composed of twenty different amino acid residues 
by a machine made up of both amino acids and nucleic acids.  Additionally, in order for 
this newly-synthesized amino acid polymer to become a functional biological component 
it must fold and convert from a linear polypeptide chain into a three-dimensional tertiary 
structure. 
The process of a protein folding into its native structure is directed along one or 
more specific free energy pathways in which each conformation is specifically restricted 
by a set of steric, attractive, and repulsive forces.  This is opposed to the protein 
randomly sampling each possible conformation (1, 2).   Along these lines, one of the 
principle forces that direct protein folding is the coordinated removal of hydrophobic 
amino acid side chains from the surrounding aqueous environment, in order to nucleate a 
hydrophobic core.  This eventually allows the rest of the amino acid residues to assemble 
the secondary structures and tertiary interfaces that collapse the protein into its native 
conformation (2). 
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According to the Anfinsen theory, the ability of a protein to fold into its structure 
is an inherent property of its primary amino acid sequence, based on observations that 
small denatured proteins are capable of spontaneously re-folding back into their native 
conformation in vitro (3).  However, in vivo the ability of a nascent polypeptide to 
spontaneously fold into the correct conformation is much more difficult due to the cell’s 
congested and dynamic environment which has an estimated protein concentration of 300 
mg/ml (4). This environment creates a competition between the intramolecular 
interactions with the protein itself and the intermolecular interactions with the 
surrounding proteins.  Thus, as a polypeptide folds, other proteins are able to interact 
with it and possibly prevent it from folding into its native conformation. This can then 
lead to aggregation of the polypeptide with other mis-folded proteins, which is often 
harmful to the cell.  This potential for aggregation is especially prevalent for proteins 
with multiple domains which must be properly oriented within the protein itself, in order 
to remain stable and functional (5).   
To prevent possible mis-folding of polypeptides, cells have developed a number 
of efficient mechanisms that assist proteins in proper folding.  The components that 
mediate these mechanisms are proteins themselves and are referred to as molecular 
chaperones, due to their ability to assist in folding polypeptides into their correct 
conformation without remaining associated with the final folded protein product.  Thus in 
as sense, molecular chaperones play a role critical in vivo in maintaining the conversion 
of genetic information into the functional molecular machines needed to sustain life 
(reviewed in (6-8)). 
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Molecular chaperones are highly conserved proteins that are present in all cell 
types, and are constitutively and inducibly expressed.  Because the expression levels of a 
number of chaperones are elevated during times of heat shock or glucose-deprivation, the 
designations heat shock protein (Hsp) and glucose-regulated protein (Grp) arose.  
Subsequently, expression of these proteins was found to be inducible by other cellular 
stresses.  In the cytoplasm, chaperones can bind directly to the ribosome, such as the 
peptidyl-prolyl isomerase trigger factor (TF) in Escherichia coli, and the 70 kDa heat 
shock protein (Hsp70) family members Ssb1 and Ssb2 and the ribosome associating 
complex (RAC) in Saccharomyces cerevisiae.  Other members of the Hsp70 family 
(DnaK homologues in bacteria) along with their cohorts help fold newly synthesized 
polypeptides and direct them to larger multimeric chaperonins, such as the GroEL ring 
complex in bacteria or the TRiC ring complex in eukaryotic cells. Nascent polypeptides 
can also be folded and directed to the TRiC complex by the GimC/prefoldin chaperones 
which are found in both archea and eukaryotic cells, but not bacteria.  Also, working in 
concert with Hsp70, is the molecular chaperone Hsp90, which has been the focus of a 
large number of studies, including this one due to its specific and unique set of substrates 
or “client proteins” that it chaperones (reviewed in (6, 9-11)). 
 
Hsp90  
Hsp90 is a vital ATPase driven molecular chaperone that is required for viability 
in all eukaryotic cells.  Expressed at high levels, Hsp90 consists of 1-2% of the total 
cytosolic protein in a cell and during times of stress, expression can rise above 4% (12, 
13).  This level of expression reflects the role of Hsp90 not only in folding, but also in 
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maintaining the activity and stability of a wide variety of specific proteins.  Though, the 
method through which Hsp90 recognizes such a diverse, yet explicit set of protein clients 
is not understood.   
Many of Hsp90’s client proteins are responsible for the transduction of the signals 
that cue a cell to grow, divide, differentiate, die or simply adjust to its dynamic 
environment.  For this reason Hsp90 is often referred to as the “signal transduction 
chaperone”.  Client proteins include steroid hormone receptors, transcription factors, and 
protein kinases, among others (Table 1).  However, Hsp90 and its cohorts do not only aid 
in the biogenesis of these client proteins, but also help regulate their activity by 
maintaining them in an inactive, yet activatable conformation.  For example, Hsp90 is 
required to maintain steroid hormone receptors in a conformation that can efficiently bind 
ligand, or in the case of other clients, to be post-translationally modified or activated by 
some other protein-protein interaction (reviewed in(9, 14, 15)).  This ability to fold and 
regulate these signal transduction proteins places Hsp90 at the crossroads of most all 
signal transduction pathways.  Although only a few members of a signaling pathway may 
actually interact with Hsp90, as is often seen in protein kinase cascades, the maintenance 
of these few members is crucial for the integrity of the entire signaling pathway.  In 
addition, Hsp90 has been shown to be able to act as evolutionary buffer that can support 
the conformational diversity of signal transduction proteins that have undergone 
mutational drift, thereby at times masking genotypic differences (16-19) This may be 
especially important in the development of certain transformed cell populations, as Hsp90 
seems to support the function of numerous proto-oncogenic client proteins (20-23). 
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The ability of Hsp90 to support these aberrant cell populations makes it a 
promising target for cancer therapy. As it is, the benzoquinone ansamycin derivative 17-
AAG (17-allylamino-17-demethoxygeldanamycin), a potent inhibitor of Hsp90’s ATPase 
activity, was the first Hsp90-inhibitor to reach clinical trials for the treatment of various 
cancers (24, 25). Currently, there are 26 ongoing cancer trials in various phases based on 
Hsp90 inhibition (24-27).  
 
 Hsp90 Relatives  
In eukaryotic cells, Hsp90 exists primarily in the cytoplasm with family members 
also found the endoplasmic reticulum, mitochondria and chloroplast.  Prokaryotes also 
have an Hsp90 homologue called HtpG (28), which is most likely the original version of 
the molecular chaperone. However, unlike eukaryotic Hsp90, HtpG is not required for 
viability under normal growing conditions.   In mammalian cells, two genes code for 
cytosolic Hsp90 with human Hsp90α having 85% sequence identity to human Hsp90β.  
Across evolution Hsp90 is also highly conserved with human Hsp90α being 60% 
identical to yeast Hsp90 and 40% identical to E. coli HtpG.  
One of the major differences between the two mammalian genes is their 
expression levels.  Hsp90α is induced upon heat shock and other stresses, whereas 
Hsp90β seems to be constitutively expressed and is sometimes referred to as Hsc90 (29, 
30).  The enigmatic Hsp90 family member responsible for the chaperoning of proteins 
that transverse the endoplasmic reticulum is known as Grp94 (94 kDa glucose-regulated 
protein) (31).  In humans, Grp94 is 46% identical to Hsp90α, and has two unique N-
terminal and C-terminal extensions.  The remaining mammalian Hsp90 family member, 
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Trap1 (tumor necrosis factor receptor associated protein type 1) or Hsp75 is 35% 
identical to Hsp90β and resides primarily in the mitochondria (32), despite its name 
which suggests a more cytosolic function.  Trap1 has also been found to bind the 
retinoblastoma protein in the cytosol (33).   
 
 Hsp90 Protein Structure 
Functional Hsp90 exists as either a homodimer (α−α, β−β) or a heterodimer 
(α−β) with its quaternary structure dictated by its ATPase activity (34-36).  Each Hsp90 
monomer consists of four defined domains: an N-terminal ATPase domain (NAD), a 
charged linker domain (LD), a middle domain (MD), and a C-terminal dimerization 
domain (CD) (Fig. 1 and Fig.2).   
The NAD is the most conserved domain of Hsp90 with its ATP binding cleft 
roughly spanning residues 1-220.  X-ray crystal structures of the both yeast and human 
N-terminal domain of Hsp90 have been solved and show that it consists of a series of 
exposed curved anti-parallel β-sheets on one side meshed against a series of α-helices, 
with the ATP binding pocket found between the β-sheets and the α-helices (37-39).  This 
pocket is also the site where the Hsp90 inhibitor geldanamycin (GA) binds, a 
benzoquinone ansamycin antibiotic which induces Hsp90 to adopt the ADP bound state 
(40-42). 
The unusual fold of the N-terminal domain of Hsp90 is known as a Bergerat fold, 
and is similar to other ATPases belonging to the GHKL family, which consists of DNA 
gyrases, helicases, and histidine kinases (43, 44).  In each protein, ATP binding, 
hydrolysis, and exchange is utilized to drive the conformational changes that confer their 
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activity, with ATP binding in Hsp90 causing the dimerization of the NAD.  This is 
coupled with the constitutive dimerization of the CD, which results in a ring-like 
structure, which is often referred to as the “molecular clamp” (45).  This ATP-bound 
conformation with the client results in its tight interaction with Hsp90, which is also 
referred to as the “slow on/slow off” conformation.  In contrast, the ADP-bound 
conformation of Hsp90 is referred to as the “fast on/fast off” conformation due to its 
weak interaction with the client protein (46). 
As alluded to earlier, the ADP-bound conformation can be mimicked by the 
binding of GA to the nucleotide binding cleft, thus disrupting the ability of Hsp90 to bind 
ATP and dimerize into its “molecular clamp”(37).   This results in the disruption or 
weakening of the interaction between Hsp90 and its client, as it is the “clamping” action 
that is predicted to provide Hsp90 with its molecular chaperoning activity. Conversely, 
the transition metal oxyanion molybdate binds to the same nucleotide binding site and 
locks Hsp90 in an ATP-bound conformation and stabilizes the Hsp90-client 
heterocomplex (47, 48).   
Interestingly, the biologically essential ATPase activity of Hsp90 has been found 
to be quite weak with additional downstream residues providing both activity and 
inhibition (49-52).  This suggests that Hsp90 ATPase activity is tightly regulated and 
most likely dependent on both client and cohort interactions.  Additionally, the NAD is 
the binding site of Cdc37, an Hsp90 cohort required for client protein kinase interaction 
(53). 
 The LD of Hsp90 is the least conserved domain in both composition and length 
with it being completely absent in some Hsp90 homologs, such as HtpG and Trap1.   
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Co-chaperones: 
 Cdc37 
 p23, and relatives SGT1, RAR1, 
SIP, and Chp1 
 Hop 
 Hsp70 and Hsc70 
 Human DnaJ homolog Hsj1 
 S100A1 
 Sse1 
 Immunophilins: FKBP51, FKBP52, 
and Cyclophilin 40 
 Other TPR proteins: PP5, TTC4, 
CHIP, UNC-45, CRN, WISp39, 
Tah1, NASP 
 p97 vasolin containing protein 
(VCP) 
 Aha1, possibly 
 
Transcription Factors: 
 Vertebrate steroid hormone 
receptors: GR, MR, ER, PR, AR 
 CAR 
 Cytoplasmic v-ErbA 
 PPARα 
 PXR 
 Hap1 
 HSF-1 
 Mal63 
 p53 
 PAS family members: Dioxin 
receptor, Sim, HIF-1, 2, 3 
 
Protein kinases: 
 pp60v-src, c-Src 
 Src family tyrosine kinases: Lck, 
Yes, Fps, Fes, Fgr, Fyn 
 Cyclin dependent kinases: Cdk4, 
Cdk6 Cdk9, Cdk11 
 Raf-1, B-Raf, Ste11 
 eIF-2α kinases: HRI, PKR, Gcn2, 
Perk 
 ErbB2 
 Akt/PKB 
 Bcr-Abl 
 Casein kinase II 
 Chk1 
 Death domain kinase RIP 
 eEF-2 kinase 
 Flt3 
 GRK2 
 IKK α,β,γ,ε 
 Insulin receptor 
 Integrin-linked kinase 
 IRAK-1 
 Ire1 
 c-Kit mutant 
 Lkb1 
 MEKK1 and MEKK3 
 MEK 
 Mik1 
 MLK3 
 MOK, MAK, MRK 
 c-Mos 
 NIK 
 PDK1 
 Pim-1 
 Pik1 
 Plk1 
 NAL kinase 
 Slt2 
 SSTK 
 TAK1 
 TBK1 
 trkB 
 VEGFR2 
 Wee1, Swe1 
 
Others: 
 Apaf-1 
 DNA polymerase α 
 Mdm2 
 Na+-K+-Cl- cotransporter 1 
 Rab-αGDI 
 Hepatitis B RTase 
 Telomerase
 
Table 1.  A represenatative list of current Hsp90 interacting proteins. Proteins that 
assist Hsp90 in folding other proteins are referred to as co-chaperones. Whereas proteins 
that are folded by Hsp90 and its co-chaperones are referred to as client these include: 
transcription factors, protein kinases, and a variety of other proteins.
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Fig. 1.  Structure of the Hsp90 N-terminal ATPase domain and geldanamycin. X-ray 
crystal structures of (A) yeast NAD in the ATP bound conformation (PDB: 1AM1) (39), 
(B) structure of GA. 
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Fig. 2.  Structure of the Hsp90 middle domain and C-terminal domain. X-ray crystal 
structures of (A) yeast MD (PDB: 1HK7) (54), (B) E.coli HtpG CD homodimerized 
(PDB: 1SF8) (55), (C) color representation of each Hsp90 domain. 
 
 
 
 
 
 
 
A 
B 
C 
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Made up of primarily charged residues, the linker domain has been shown to contain two 
casein kinase II (CKII) phosphorylation sites and a possible nuclear localization sequence 
(NLS) (56-58).  Furthermore, its presence in N-terminally truncated Hsp90 mutants, 
masks Hsp90’s CD nucleotide binding site.  However, despite these signs that it may play 
a role in regulating Hsp90 activity, the charged LD has also been shown not to be 
required for viability in yeast (59). 
The X-ray crystal structure of the MD of yeast Hsp90 reaffirms the association of 
Hsp90 with the GHKL family of ATPases (54).  Made up of a three layer α-β-α 
sandwich architecture the MD is predicted to contain the catalytic lysine that confers 
Hsp90’s ATPase activity much like its GHKL relatives.  The MD may also be directly 
involved in client/substrate interaction, while it is also the binding site of the peculiar 
cohort AhaI (60).   
The 12 kDa CD is responsible for the majority of the interactions between Hsp90 
monomers that drives Hsp90’s dimerization.  Dimer formation may also play an 
important role in regulating Hsp90’s ATPase activity due to the fact that C-terminal 
truncation mutants of yeast Hsp90, which are unable to properly form dimers, exhibit 
greatly reduced ATPase activity (52).  The C-terminal domain is also the binding site of 
numerous cohorts known as TPR (tetratricopeptide-repeat) proteins, which bind to the 
conserved C-terminal EEVD motif of Hsp90.   An EEVD motif is also found at the C-
terminus of Hsp70, due to the need of some TPR proteins to bind to both chaperones (61-
64).  Additionally, the CD of Hsp90 has been shown to contain a second nucleotide 
binding site, which plays a role in coordinating specific interactions of Hsp90 with its 
client proteins and modulates the nucleotide-binding affinity of its NAD (65-68).  
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However, whether this site functions as a second ATPase that helps drive protein folding 
or a site for allosteric regulation is not fully understood.  Moreover, this is the binding 
site of the Hsp90 inhibitor novobiocin, which has also been shown to cause client protein 
dissociation (68). 
 
 
Hsp70 and Co-chaperones 
In order for Hsp90 to fully function as the “signal transduction chaperone” in 
vivo, the assistance of numerous partner proteins is required.  These partner proteins 
known as cohorts or co-chaperones often possess molecular chaperone capabilities of 
their own, as well as inducible expression in response to many forms of cellular stress, 
such as heat shock.  The roles of these co-chaperones in aiding Hsp90 have been shown 
to be quite diverse while some their roles are not completely understood.  Some co-
chaperones appear to help pre-fold the client protein and target them to Hsp90 for further 
folding, while also possibly modulating the ATPase and concomitant client folding 
activity of Hsp90.  Whereas, it seems other co-chaperones interact directly with Hsp90, in 
order to direct client protein trafficking or remove certain post-translational 
modifications.   
 
 Hsp70 Chaperone Network  
The highly conserved Hsp70 family of molecular chaperones makes up the 
centerpiece of a ubiquitous chaperone network that is able to fold a wide range of client 
proteins with the assistance of various co-chaperones.  Several homologs of Hsp70 are 
found in prokaryotes, with the predominant homolog being known as DnaK.  In 
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eukaryotes, Hsp70 homologs are present in the cytosol, ER, lysosome, mitochondria, and 
chloroplast.   In mammals, two cytosolic isoforms are commonly expressed, the 72 kDa 
stress-induced Hsp70 and the 73 kDa constitutively expressed Hsc70 (14, 15, 69, 70). 
Hsp70 is made up of three domains:  an N-terminal 44 kDa ATPase domain, a 12 
kDa peptide binding domain, and a 10 kDa C-terminal tail domain that often terminates 
with an EEVD motif like Hsp90.  However, unlike Hsp90 in regards to substrate binding, 
ATP-bound Hsp70 is referred to be in the “fast on/fast off” conformation, while ADP-
bound Hsp70 is referred to be in the “slow on/slow off” conformation.  Also unlike 
Hsp90 whose client binding specificity is not well understood, Hsp70 has been 
determined to bind short extended linear polypeptides enriched in hydrophobic residues, 
most likely in order to prevent the aggregation of the exposed hydrophobic portion of a 
protein (69-71).  Thus, Hsp70’s binding specificity and activity concurs with Hsp70 
being a general molecular chaperone aiding in the folding of an extremely wide variety of 
proteins.   
To help fold this wide variety of proteins, Hsp70 is aided by several co-
chaperones that regulate its ATPase activity.  Activation of Hsp70 ATPase activity is 
stimulated by J-domain containing proteins, such as Hsp40s, which are homologous to 
DnaJ proteins in prokaryotes.  As it is, Hsp40/DnaJ proteins possess their own chaperone 
activity and seem to bind to the substrate first and subsequently recruit it to Hsp70.  The 
Hsp40 family consists of 44 members in humans, which allows DnaJ homologues to bind 
unique sets of substrates at different locations within the cell. This then provides a certain 
level of substrate specificity to Hsp70 which otherwise interacts with proteins rather non-
specifically (reviewed in (70, 72).   
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 Exchange of ADP and release of substrate is next facilitated by the nucleotide 
exchange factors, Bag and HspBP1, or their functional analog GrpE in prokaryotes (73-
75).  Additionally, in mammalian cells Bag-proteins and HspBP1 compete with the 
Hsp70 interacting protein, Hip, which stabilizes the ADP-bound form of Hsp70 and 
thereby prolongs substrate binding (76). 
Six human Bag proteins have been reported so far.  Bag-family proteins bind to 
the ATPase domain of Hsc70/Hsp70 via their C-terminal Bag-domain.  Bag domains 
consist of approximately 110 amino acids that form three anti-parallel α-helices and are 
responsible for their nucleotide exchange activity.  Several N-terminal domains or motifs 
that enable BAG-family proteins to partner with other proteins have been identified.  
These domains, like the additional domain found in DnaJ homologs are thought to enable 
BAG-family proteins to facilitate the release or the recruitment of specific client proteins 
to Hsc70/Hsp70 (70). 
 
 Hop 
Identified as a component of the Hsp90 steroid hormone receptor complexes, Hop 
has been determined to provide a link between the Hsp70 chaperone network and the 
Hsp90 chaperone machine (77, 78).  Comprised of three TPR (tetratricopeptide or 34 
residue repeat) domains Hop is able to bind the EEVD motifs of both Hsp70 and Hsp90: 
hence its name Hsp90/Hsp70 organizing protein (Hop).  Residues upstream of the EEVD 
motifs provide the binding specificity between each TPR domain, with the first domain 
(TPR1) binding Hsp70 and the middle domain (TPR2a) binding Hsp90 (Fig. 3). The 
polypeptide ligand for the third domain (TPR2b) has not been determined (14, 61, 63).  
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Further evidence indicates that Hop does not only passively link Hsp70 and Hsp90, but 
may also regulate their ATPase activity, with the binding of Hop stimulating Hsp70’s and 
inhibiting Hsp90’s ATPase activity, respectively (79-81). This property of Hop, in turn 
possibly coordinates protein client exchange between the two chaperone machines.  The 
complex containing Hsp70, Hop, Hsp90 and the client protein is often referred to as the 
“intermediate complex” because it lies at the junction between the two major folding 
cycles of Hsp70 and Hsp90, with the “early complex” consisting of Hsp70 and its 
specific co-chaperones and the “late complex” consisting of Hsp90 and its specific co-
chaperones (14, 15).   
 
 p23 
A small yet complex protein, p23 is another Hsp90 co-chaperone that was 
originally identified in steroid hormone receptor complexes (82, 83). A member of the 
Hsp90 “late complex”, p23 binds directly to dimerized ATP-bound Hsp90 and aids in 
facilitating client protein folding.  Highly conserved from yeast to humans, p23 is 
comprised of a compact 8 β-sheet sandwich (Fig.3) with an acidic tail that is often 
phosphorylated (84).  As it is, the acidic tail is needed for p23’s passive chaperoning 
activity of denatured proteins along with the cooperative chaperoning of Hsp90 client 
proteins (reviewed in(85). 
Evolutionary tracing methods and mutagenesis experiments predict that the direct 
binding of p23 to Hsp90 is carried out by the β-sheet sandwich of p23 and the dimerized 
N-terminal ATPase domain of Hsp90 (86). This supports data indicating that p23 plays a  
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Fig. 3.  X-ray crystal structures of the TPR2a domain and p23.  (A) TPR2a domain of 
Hop (yellow)bound to the MEEVD motif of Hsp90 (green) (64); (B) N-terminal β-sheet 
domain of p23 (84).  
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critical role in stabilizing the interaction of ATP-bound Hsp90 with client proteins (46), 
although some reports suggest that p23 may also play a role in client protein release (87).  
 
  Other TPR Co-chaperones 
Besides Hop, Hsp90 binds a large set of other TPR co-chaperones that are present 
only in the “late complex”. These co-chaperones bind to the C-terminal EEVD motif of 
Hsp90 through their TPR domains, but contain other non-TPR domains that function in 
the folding or the maturation of the client protein. Immunophilins, which possess 
domains with peptidyl-prolyl-cis-trans isomerase (PPIase) activity upstream of their TPR 
domains, are required for proper steroid hormone receptor signaling and receptor 
transport.  These immunophilins which are named for their ability to bind 
immunosuppressive drugs include FKBP51, FKBP52 (FK506-binding protein) and 
Cyp40 (cyclosporin A-binding protein) (reviewed in (15, 88, 89). PP5 (protein 
phosphatase 5) is a TPR protein whose phosphatase activity has been found to modulate 
the maturation client protein kinases (90).  Another “late” TPR protein, TTC4 is 
predicted to help assemble DNA replication complexes and is currently being studied in 
our lab.   
 AhaI 
 The AhaI/HchI proteins are the most recent additions to the Hsp90 chaperone 
machine.  HchI, an abbreviated homolog of AhaI, was originally identified as a high copy 
suppressor of the E381K mutant Hsp90 in yeast (91).  Moreover, AhaI has been shown to 
stimulate the ATPase activity of yeast Hsp90 by up to 12 fold (92, 93). Further studies 
have also determined that AhaI directly binds to the middle domain of Hsp90 with the  
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Fig. 4.  X-ray crystal structure of AhaI bound to the Hsp90 MD.  AhaI (cyan) binds to 
the “backside” of the MD (red) of Hsp90. In the manuscript describing the interaction 
another orientation was shown in which AhaI bound to the “front side” of the MD (60). 
However, this orientation can not be found in the PDB.  
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crystal structure showing two different orientations (Fig. 4) (54, 60).  Additionally, 
published reports suggest that AhaI helps Hsp90 facilitate both steroid hormone receptor 
and protein kinase maturation (91, 94, 95).  These findings however conflict with the 
current work done in our lab which suggests that AhaI interacts with Hsp90 in a manner 
similar to a client protein, and has no direct interaction with Hsp90-kinase or Hsp90-
steroid hormone receptor complexes. 
 
Cdc37 
Cdc37 or p50 is currently understood to be the co-chaperone that is specifically 
responsible for the partial folding and recruitment of client protein kinases to the Hsp90 
chaperone machine (reviewed in (96, 97)).  Yet, how Cdc37 recognizes client kinases and 
specifically modulates the chaperoning process with Hsp90 is not understood.  Initially 
identified as a cell-division cycle mutant that arrests S. cerevisiae in G1 (98), Cdc37 was 
later found in mammalian cells to physically interact with Hsp90 and the Rous sarcoma 
viral kinase pp60v-src (99).  Cdc37 since then has been found to interact with a variety of 
other protein kinases in concert with Hsp90, while also being shown to be essential for 
the viability of S. cerevisiae (100), Caenorhabditis elegans (101) and Drosophila 
melanogaster (102).   
The importance of Cdc37 for viability is further illustrated by its requirement to 
support the function of several client protein kinases that transduce pro-growth signals. 
Determined to be the only co-chaperone whose level of expression can considerably 
affect cell proliferation (103), Cdc37 expression has been found to be drastically higher 
in human prostatic cancers and pre-malignant neoplasias (104).  Ectopic overexpression 
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in transgenic mice has been shown to promote the formation of mammary tumors with 
Cdc37 also working in synergy with c-Myc in the transformation of salivary and 
testicular tissue (105).  These studies in turn have implicated Cdc37 as an indirect yet 
highly influential proto-oncogene that helps maintain or possibly promote many of the 
pro-growth signals upon which tumors become dependent on. 
Continuously required to maintain the population of client kinases, Hsp90 and 
Cdc37 can specifically interact with both nascent kinases emerging as polypeptides from 
the ribosome and fully mature protein kinases that depend on Hsp90 and Cdc37 for their 
ongoing cellular stability (106).  These interactions, however, do not simply reflect 
Cdc37 acting as a scaffold, linking the client kinase to Hsp90.  Experimental data indicate 
that Cdc37 also modulates Hsp90 nucleotide-mediated conformational switching which 
causes both chaperones to associate with the client kinase in a synergistic manner.  Thus, 
the interaction between Cdc37 and Hsp90 and the client kinase is stabilized by the 
presence of both chaperones.  In addition, the interaction between Cdc37 and Hsp90 
themselves is stabilized by the presence of the client kinase in the complex (107).  These 
complexes have proven to be quite stable, being able to withstand washing with high 
ionic strength buffer.  The ability of kinases to form these salt stable chaperone 
complexes is dependent on the ATP-induced dimerization of Hsp90’s NAD into its 
“molecular clamp” conformation, which somehow secures both Cdc37 and the client 
kinase in a hydrophobic embrace (107, 108).  This complex is then disrupted by the 
hydrolysis of the ATP to ADP causing the release of both the client kinase and Cdc37.  
Similarly, the high affinity binding of GA to Hsp90 causes the same constitutive effect as 
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ADP binding (107), which often leads to client kinase destabilization within the cell 
(reviewed in (23)). 
Interestingly, Cdc37 itself has also been found to inhibit the ATPase activity of 
Hsp90 much like Hop (109).  Although, exactly how this inhibition helps modulate 
Hsp90’s nucleotide-mediated conformational switching, and therefore the chaperoning 
process is not completely understood. This activity of Cdc37 suggests that it would allow 
for a prolonged interaction with the client kinase and Hsp90, therefore allowing the client 
kinase to eventually fold into its proper conformation.  Additionally, Cdc37 is predicted 
to work in conjunction with other “late co-chaperones” such as the immunophilins, PP5, 
TTC4, and p23 (90, 96, 97, 107).  Furthermore, although it has been reported in the 
literature that Cdc37 is able to bind Hsp90 along with AhaI in vitro (95), current work in 
our lab has shown that Cdc37 is not present in AhaI-Hsp90 complexes. 
Despite it being essential for viability, Cdc37 is poorly conserved throughout 
evolution sharing only 20.5% amino acid identity between the mammalian and yeast 
homologues.  The lack of conservation is also denoted by the differences in size with 
yeast being 506 residues and human only 378 residues.  The most conserved region of 
Cdc37 is the first 40 amino acids which is over 50% identical between yeast and human. 
Notably, this N-terminal region has been determined to be the kinase binding domain 
(KBD) (106, 110).  Truncated mutants of Cdc37 containing the KBD are able to affect 
client kinase folding and stability in a dominant-negative manner by binding to the kinase 
yet not targeting it to Hsp90 for chaperoning (106, 111, 112).  Also, although Cdc37 
homologues have been found in every metazoan studied no plant homologues have been 
currently identified.  However, our lab has identified an interesting Arabidopsis thaliana 
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protein that contains an N-terminal TPR domain followed by a region that resembles the 
first 40 amino acids of yeast and human Cdc37.  Studies to resolve whether this protein 
truly is a plant Cdc37 homologue are currently being conducted.  
Domain dissection work has determined that human Cdc37 consists of three 
defined regions: the previously mentioned kinase binding domain (KBD) [residues 1-
126], the Hsp90 binding domain (HBD) [residues 127-282], and a third domain (D3) 
[residues 282-378] whose function is unknown.  Deletion of the first eight amino acids of 
the KBD has shown that the very N-terminus of Cdc37 is critical for kinase binding 
activity. Alanine scanning mutagenesis of these first eight residues indicates that both 
Tyr4 and Trp8 are needed for kinase binding with Trp8 also playing a role in Hsp90 
interaction (108).  The KBD moreover, contains a highly conserved CKII 
phosphorylation site at Ser13.  Phosphorylation of this site has proven to be functionally 
significant in allowing Cdc37 to interact with client kinases and modulate Hsp90’s 
nucleotide-mediated conformational switching which allows for the formation of the salt 
stable client-chaperone complex (108).  Interestingly, CKII itself is functionally 
dependent on Cdc37, and thus creates a positive feedback loop between the client kinase 
and the co-chaperone (113, 114). 
 The crystal structure of the human HBD of Cdc37 with the yeast NAD of Hsp90 
has been solved and depicts Cdc37 binding to the mobile “lid” segment of the ATP 
binding cleft of Hsp90 (Fig. 5) (53).  This along with Cdc37 directly inserting Arg167 
into the ATP binding cleft suggests how Cdc37 is able to inhibit the ATPase activity of 
Hsp90.  The crystal structure also depicts the Cdc37 HBD as a dimer that binds Hsp90 on 
either face, which would further prevent the N-terminal domains of Hsp90 from forming  
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Fig. 5.  Structure of Cdc37.  (A) X-ray crystal structure of human Cdc37 HBD and D3 
bound to yeast Hsp90 NAD (53). Cdc37’s KBD is not shown. (B) Color representation of 
Cdc37’s functional domains.  
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their own dimer upon ATP binding.  This conformation is proposed to hold open the 
“jaws” of the “molecular clamp”, and is predicted to facilitate the loading of the client 
kinase.  D3, which was also partially solved in this crystal structure, is a globular helical 
bundle following the extended helix of the HBD. What the function of this domain is 
remains unknown but it is speculated that the large extended helix may indeed be a 
crystallization artifact.  In yeast both the HBD and D3 are expendable, in part. Cdc37 
mutants truncated after the HBD function the same as wild-type, whereas mutants 
truncated after the KBD are only partially functional.  The true relevance of this crystal 
structure to mammalian Cdc37, however should be considered with caution since these 
domains are the least conserved throughout evolution.  
 The HBD of Cdc37has been discovered in another protein called Harc (Hsp90-
asociating relative of Cdc37). A 35 kDa protein, Harc is 31% identical to human Cdc37 
with the HBD’s being 62% identical (115).  The other two domains of Harc hold little 
homology to those of Cdc37.  Originally identified in humans, Harc has been found to 
exist only in vertebrates with its mRNA expressed primarily in the liver, skeletal muscle, 
kidney and heart (115).  Curiously, little is known about Harc’s function and whether or 
not it acts similarly to Cdc37 and recruits a specific population of client proteins to be 
chaperoned.  Currently, our lab is studying Harc in hopes of answering this question and 
to further determine its function as an Hsp90 co-chaperone. 
The mystery of Cdc37 persists in its interactions with its clients, as it is not 
understood why some kinases are clients of Hsp90 and Cdc37 and some kinases are not.  
Equally interesting is the fact that Cdc37 associates with non-kinase Hsp90 clients. For 
example, Cdc37 interacts with the ligand binding domain of the androgen receptor in a 
 25
manner reminiscent of its client kinase interactions, but not with the closely related 
glucocorticoid receptor (GR) (112).  Cdc37 also has been found to specifically interact 
with the reverse transcriptase of the duck hepatitis B virus, which is predicted to be 
structurally similar to the client kinase Raf-1 (116).   
 
Hsp70/Hsp90 Chaperone Cycle 
The Hsp70/Hsp90 chaperone cycle was originally described by Smith et al. to 
explain the mechanisms and interactions of steroid hormone binding activity for both the 
glucocorticoid and progesterone receptors (117).  In rabbit reticulocyte lysate, assembly 
of receptor-Hsp90 heterocomplexes was found to require ATP, Mg2+, a monovalent 
cation such as K+, and Hsp70.  Further work identified Hsp40, Hop, and p23 as 
components that each associated with the chaperone heterocomplex at different points of 
the cycle. Eventually, it was then shown that it was possible to assemble a steroid 
hormone receptor-Hsp90 heterocomplex  in  vitro using purified proteins.  This minimal 
system sometimes referred to as the foldosome consists of Hsp40, Hsp70, Hsp90, Hop, 
and p23.  However, although this five purified protein system has been essential in 
elucidating the Hsp70/Hsp90 chaperone cycle it has been used primarily to describe the 
chaperone interactions with steroid hormone receptors, with much still to be determined 
about other client proteins, such as kinases. 
Client proteins folded by the Hsp70/Hsp90 chaperone cycle are processed and 
passed from one complex to another with different sets of chaperones in each complex 
(Fig. 6).  In the “early complex” Hsp70 and its cohorts bind to the hydrophobic motifs of 
the client polypeptide allowing the core of the polypeptide to collapse.  The partially 
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folded client is then passed on to Hsp90 and its cohorts within the “intermediate 
complex”. The Hsp90 chaperone machine then folds and rearranges the tertiary and/or 
quaternary structure of the client protein in the “late complex”.  The folded client protein 
is then released to carry out its function.  However, some client proteins are inherently 
unstable and are taken back into the cycle repeatedly until they are properly modified or 
bind ligand, as is the case for steroid hormone receptors.  
The Hsp90/Hsp70 chaperone process is first initiated by the binding of an Hsp40 
or a DnaJ homologue to the client polypeptide, which may exist as either a nascent 
polypeptide or a mis-folded protein.  The client polypeptide is then recruited to Hsp70 
where Hsp40 stimulates the ATPase activity of Hsp70 with its J-domain causing Hsp70 
to bind tightly to the hydrophobic stretches of the polypeptide.  This is referred to as the 
“early complex”. At this point several different things can then happen depending on 
which co-chaperone binds next. If the nucleotide exchange factor Bag-1 binds it causes 
Hsp70 to exchange bound ADP for ATP, and the client protein to be released from the 
“early complex”.  However, if the TPR domain co-chaperone Hip binds to Hsp70 instead, 
the “early complex” will be stabilized in the ADP bound form.  It is likely that Hsp40 in 
these complexes is displaced since all three co-chaperones associate with the N-terminal 
ATPase domain of Hsp70, although Hsp40 in some instances may still associate with the 
polypeptide through its client binding domain.   
If the TPR protein Hop binds, the “early complex” becomes the “intermediate 
complex”, as Hop bridges Hsp70 to Hsp90.  In the “intermediate complex” it may be 
possible for Hsp40 to be present since Hop coordinates both Hsp70 and Hsp90 by 
binding to their C-terminus EEVD motifs.  Additionally, the observed  
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Fig. 6.  Hsp70/Hsp90 Chaperone Cycle description adapted from (15). “Early 
complex” chaperones such as Hsp40 and Hsp70 associate with nascent polypeptides as 
they emerge from the synthesizing ribosome. (1) Hip displaces Hsp40 and maintains 
Hsp70 in the ADP bound state, tightly binding the polypeptide, or (2) Bag displaces 
Hsp40 and causes Hsp70 to release both the polypeptide and ADP, or (3) Hop binds 
Hsp70 via its TPR1 domain and recruits Hsp90 to form the “intermediate complex”. (4) 
Hsp90 dimerizes its NADs upon ATP binding while “late complex” chaperones such as 
p23, Cdc37, PP5, and immunophilins associate. Hsp70 and Hsp40 are then allowed to 
dissociate. (5) The client protein is further folded by Hsp90 and its cohorts into a mature 
protein.  In this complex the client protein may also be acted upon by other components 
such as kinases and phosphatases or bind ligand upon release. (6) Although, the mature 
client may be destabilized by inherent instability or loss of ligand and/or post-
translational modification. (7) Hsp40 and Hsp70 recognize the unstructured polypeptide 
and recruit it back into the early complex, or (8) the unstable protein is ubiquitinated and 
degraded by the proteosome or some other form of proteolysis, or (9) the protein is 
recruited back into the cycle by some other means. 
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stoichiometry of this Hsp90: Hop: Hsp70 complex is 2:1:1, suggesting that only one of 
the Hsp90 dimer is interacting with the Hop-Hsp70-client heterocomplex.   
The transition from the “intermediate complex” to the “late complex” is not well 
defined, but consists of events that allow the partially folded client protein to be 
transferred from Hsp70 to Hsp90.  The coordinated release of the client protein by Hsp70 
is followed by the dissociation of all the “early complex” components (Hsp70, Hsp40, 
Hip) and the “intermediate complex” component Hop.  On the other hand, the 
coordinated binding of the client protein by Hsp90 is followed by the association of 
several “late complex” components such as p23, immunophilins, PP5, and Cdc37.   
When GA or any of its analogs are present, Hsp90 is found to be in the ADP-
bound conformation and therefore unable to form productive “folding” complexes with 
the client protein.  This is demonstrated by the inability of Hsp90 to form “late 
complexes” with the client protein that are stable in the presence of high ionic strength.  
Moreover, since the “intermediate complex” is the first opportunity for Hsp90 to interact 
tightly with the partially folded client protein, GA inhibition is predicted to block the 
Hsp70/Hsp90 chaperone cycle at this point. This, in turn, causes the observed increase in 
Hsp70 interaction with the clients, due either to its inability to hand-off partially folded 
client proteins to Hsp90, or due to the increased population of mis-folded proteins in the 
cytosol.  In the presence of GA, unstable client proteins are then subject to higher rates of 
proteolytic degradation, typically carried out through the ubiquitination/ proteasome 
pathway (20, 118). 
“Late complexes” are characterized by the stable binding of Hsp90 and its co-
chaperones to the client proteins.  In the “late complex”, Hsp90 binds ATP and dimerizes 
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its NADs into the “clamp” conformation.  The formation of “late-complexes” also 
involves the recruitment of p23 to Hsp90.  Once p23 is bound to Hsp90, Hop binding is 
diminished.  As p23 tightly binds to the dimerized NADs of Hsp90, the client-chaperone 
heterocomplex becomes stabilized.  This is concurrent with or followed by, the binding 
of the TPR co-chaperones to the now vacated EEVD motifs of Hsp90.  These co-
chaperones are predicted to carry out their specific tasks while the client protein is held 
by Hsp90.  For steroid hormone receptors, this “late complex” conformation is required 
for the opening of the ligand binding cleft and subsequently the ligand binding activity of 
the receptor. 
Cdc37 is also present in “late-complexes” formed between Hsp90 and its clients. 
However, since it is required for the recruitment of clients, especially protein kinases, to 
the Hsp90 chaperone machine, Cdc37 may also be present in earlier complexes and 
possibly play a role similar to Hop in mediating the client exchange from Hsp70 to 
Hsp90.  Finally, once the Hsp90 chaperone machine has been fully assembled, the client 
protein is folded and released as a “mature” protein.  When ATP hydrolysis occurs and 
how the “late complex” chaperone machine is disassembled remains to be characterized.   
The release of the client protein and the dissociation of the “late” complex 
chaperones, however, can be prevented by the addition of molybdate.  Like GA, 
molybdate inhibits Hsp90 function, but instead of locking Hsp90 in the ADP bound “fast 
on/fast off” conformation molybdate appears to lock Hsp90 in its “slow on/slow off” 
conformation.  This causes the Hsp90 chaperone machine to bind the client protein in a 
high-affinity salt-resistant manner: a characteristic that is useful in studying the 
interactions between the Hsp90 chaperone machine and the client protein (48, 68, 106, 
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108, 119).  However, unlike steroid hormone receptors, which require molybdate to 
stabilize their interaction with the Hsp90 chaperone machine (117), full length protein 
kinases can form highly stable salt-resistant heterocomplexes with the “late” Hsp90 
chaperone machine independent of molybdate (48, 108).  Additionally, because 
molybdate is able to lock Hsp90 in its “slow on/slow off” conformation (48), it has been 
speculated that molybdate mimics the gamma phosphate of the hydrolyzed ATP bound to 
Hsp90.  This has led to the hypothesis that the release of the hydrolyzed gamma 
phosphate from the Hsp90 nucleotide binding cleft is an important step in Hsp90’s 
reaction cycle, and that phosphate release, not merely ATP hydrolysis, may be the trigger 
that stimulates client protein dissociation. 
Upon release, the folded client protein is then capable of functioning properly, but 
by design it may eventually be reloaded into the Hsp70/Hsp90 chaperone cycle if it 
becomes unstable due to either a loss of ligand binding, loss of a post-translational 
modification or an inability to bind the correct partner protein.  This appears to be a 
common characteristic that provides the Hsp70/Hsp90 chaperone cycle with a certain 
degree of regulation over most all signal transduction pathways.   
 
Protein Kinases 
In eukaryotic cells, protein kinases play a major role in modulating every 
biological function that allows the organism to adapt and survive.  Cell division, 
metabolism, growth, differentiation, and apoptosis are all regulated by signal transduction 
pathways that include one or more protein kinases.  Protein kinases use ATP to 
covalently attach a phosphate group to a serine, threonine, or tyrosine on the substrate 
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protein, thereby altering the protein’s conformation and electrostatic topology.  These 
alterations can then affect the substrate protein’s function, activity, subcellular 
localization, and/ or cellular stability.  Moreover, these effects can also alter the 
interactions of the phosphorylated protein with other proteins, by altering the activity of 
the substrate protein itself and/or its partner proteins.  Furthermore, since each signal 
transduction pathway must dynamically adjust to the ever changing cellular environment, 
the ability to remove the phosphate group from the substrate protein is essential: a 
reaction which is carried out by a family of enzymes known as phosphatases.  Thus, the 
specific phosphorylation state of a cell’s proteome and its ability to maintain homeostasis 
is balanced by the activities of both protein kinases and phosphatases. 
In a cell, the goal of most signal transduction pathways is ultimately to alter gene 
expression. This is, in order, to either adapt to the environment or to change the 
properties of the cell itself so that it can better serve the whole organism.  Organized as a 
network of detectors, transducers, and effectors each signal transduction pathway consists 
of several tiers with a different kinase at each tier.  Kinases at the higher tiers are 
activated by receptors or are receptors themselves that transduce signals by activating 
kinases at the intermediate tiers.  The activation of downstream kinases is typically 
achieved by phosphorylating the target kinase, in many cases within its activation loop.  
These intermediate tier kinases then transduce this signal by phosphorylating and thereby 
activating lower tier kinases. Finally, the lower tier kinases go on to phosphorylate and 
activate the effector proteins. 
The transduction of the signal along these pathways occurs in a cascade like 
manner with each kinase capable of phosphorylating numerous downstream substrates.   
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This mechanism, in turn, allows the original signal to be amplified exponentially.  Each 
kinase may also phosphorylate several different species of substrates, thereby broadening 
the effect of the original signal.  When members of a different signaling pathway are 
activated it is referred to as crosstalk between the two pathways.  These crosstalk events 
frequently serve to regulate the signal through a positive or negative feedback 
mechanism.  In the end the signaling pathway is eventually reset as each activated kinase 
is de-phosphorylated and inactivated by a phosphatase. 
Protein kinases make up at least 1-2% of all the proteins encoded by eukaryotic 
genomes, making them the third most common protein domain in the human genome 
(120).  This type of prevalent expression combined with the reality that abnormal protein 
kinase activity often leads to disease has led to protein kinases emerging as major drug 
targets.  As it is, one-third of all newly validated drug targets in the pharmaceutical 
industry are protein kinases (121).   
For general purposes protein kinases can be classified into two groups based on 
substrate specificity: tyrosine kinases (PYK) and serine/threonine kinases (PSTK).  PYKs 
are expressed predominantly in metazoans and are responsible for transducing the 
complex intercellular signals of higher eukaryotes.  Also PYKs are significantly liable for 
many human diseases, as PYKs constitute over 80% of all known proto-oncogenes.  
PYKs are typically found at the outer membrane of the cell with 58 of the 90 PYKs 
encoded by the human genome being cell surface receptors with cytoplasmic kinase 
domains (122).  These receptor PYKs function by binding extra-cellular ligands, which 
induce receptor oligomerization and subsequently the trans-autophosphorylation of their 
cytoplasmic domains. This then activates the receptor PYKs towards their intracellular 
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substrates or leads to the assembly of signal transduction modules.  These activated 
substrates or signaling modules then go on to propagate the signaling pathway.  The 
remaining non-receptor PYKs, such as the lymphoid cell kinase (Lck), also localize to the 
cytoplasmic side of the plasma membrane due to the presence of covalently bound fatty 
acids.  These peripherally associated plasma membrane kinases interact with and are 
regulated by other cell surface receptors, where they also function in transducing 
receptor-mediated signals.  
PSTKs, on the other hand, are found in both metazoan and unicellular eukaryotic 
organisms.  PSTKs, such as Cdk2 and JNK, are responsible for the regulation and 
transduction of intracellular signals.  Thus, PSTKs typically function downstream of 
PYKs in protein kinase cascades that make up the integrated signal transduction 
pathways.  
 
 Protein Kinase Structure  
The overall fold of the protein kinase catalytic domain is remarkably conserved 
across all eukaryotic protein kinase families.  Consisting of 250-300 amino acids, the 
kinase domain folds into a two-lobed structure that can be preceded and/or followed by 
any number of regulatory domains.  The two-lobed structure can be further divided into 
12 conserved structural motifs, as described by Hanks and Hunter (Fig. 7 and Table 2) 
(123).  These motifs are defined as regions containing both the conserved amino acids 
and 20 structure that are essential for the function of the kinase.  The smaller N-terminal 
lobe (NL) is composed of motifs I-V and is responsible for binding and orientating the 
ATP molecule, while the larger more stable C-terminal lobe (CL) is composed of motifs 
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V-XI and is involved in the binding of the peptide substrate and initiating 
phosphotransfer.  Structural motif V links the NL and CL together with portions of it 
often included in either lobe.  
 
 Protein Kinases Studied  
The three protein kinases that are primarily studied in this project are the 
lymphoid cell kinase (Lck), the cyclin-dependent kinase 2 (Cdk2) and the c-Jun N-
terminal kinase 1 (JNK1).  Currently, Hsp90 and Cdc37 have been shown to physically 
interact with Lck (124), but not JNK1 or Cdk2 (125).  Genetic evidence has, however, 
strongly suggested that Cdk2 interacts with Hsp90 and Cdc37 (126). A brief description 
of the structure, function, and role in signal transduction of each kinase in provided.   
 
   Lck 
Lck is a 56 kDa Src-family tyrosine kinase that is required for proper T-cell 
antigen receptor (TCR) signal transduction (reviewed in (127).  Lck is made up of six 
defined domains: 1) an N-terminal fatty acid attachment domain, 2) a unique domain; 3) 
a Src-homology 3 (SH3) domain; 4) an SH2 domain; 5) the tyrosine kinase domain; and 
6) a C-terminal inhibitory tail domain (CITD).  The N-terminal fatty acid attachment 
domain is the site where Lck is myristoylated and palmitoylated, which allows Lck to 
localize to the plasma membrane and translocate to lipid rafts, respectively.  The unique 
domain utilizes the coordination of a Zn2+ ion to mediate its interaction with the T-cell 
co-receptors, CD4 and CD8.  The SH3 domain is a poly-proline binding domain that aids 
in the inhibition of Lck and the binding and localization of signal transduction particle  
 35
 
 
 
 
 
 
 
 
 
Fig. 7. Structure of the catalytic kinase domain of Lck. Using the kinase domain of 
Lck as a reference each structural motif is depicted by a different color and explained in 
Table 2. The kinase domain is shown with its ATP binding cleft facing either (A) toward 
or (B) away from the viewer.  
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Structural 
Motif 
Residues Color Information 
I 245-266 Red Two β-strands which contain the G-
box motif, GXGXXG. Covers and 
anchors the non-transferable 
phosphates of ATP. 
II 267-280 Yellow β-strand 3 which contains an 
invariant catalytic Lys. 
III 281-295 Cyan α-helix C which contains an invariant 
Glu needed for stabilizing the α and β 
phosphates of ATP. 
IV 296-310 Magenta Hydrophobic β-strand 4 with hinge-
loop motif. 
V 311-336 Orange Connects the NL and CL, 
hydrophobic random coil and α-helix 
D, may also contain large regulatory 
insertion sequences. 
VIA 337-358 Blue Large α-helix E where hinge-loop 
motif pivots on. 
VIB 359-375 Green Catalytic loop (HRDLK/RXXN) and 
β-strand 6. 
VII 376-388 Red orange β-strand 7 contains the DFG motif, 
which coordinates Mg2+ or Mn2+ ions.
VIII 389-415 Green blue Contains the APE-box motif which 
salt-bridges with an invariant Arg in 
XI. Plays a major role in substrate 
recognition and activation, may be 
phosphorylated by activating kinases. 
IX 416-443 Violet Large α-helix F contains an invariant 
Asp which stabilizes the catalytic 
loop. 
X 444-464 Cyan α-helix G poorly conserved, function 
is unclear. 
XI 465-501 Purple α-helices H and I contain an invariant 
Arg which salt-bridges with Glu in 
VIII. 
 
 
Table 2. Summary of the Structural Motifs of Protein Kinases.  Each structural motif 
is designated by a roman numeral according to Hanks and Hunter. A different color is 
given for each motif according to Fig. 7.  A brief description of each motif is given with 
the β-sheets being numbered 1-7 and the α−helices designated A-I. 
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components containing poly-proline II type helical motifs.  The SH2 domain is a 
phospho-tyrosine binding domain that binds to phosphorylated Y505 located in the 
CITD, which in turn inhibits Lck kinase activity. The SH2 is also responsible for docking 
of Lck to signal transduction particle components containing phosphotyrosine.  The 
tyrosine kinase domain functions as previously described.  
The activation of Lck and transduction of the TCR signal are highly dependent on 
two factors; the phosphorylation state of Lck and its localization (reviewed in (127).  
When Y505 of Lck is phosphorylated by Csk1 the SH2 domain intramolecularly binds to 
the CITD and locks down the tyrosine kinase domain. This interaction also causes the 
SH3 domain to bind to a poly-proline motif within Lck that further inhibits kinase 
activity.  Once Y505 is de-phosphorylated by the phosphatase CD45, Lck is said to be in 
its “primed” state and is capable of being activated.  Upon TCR activation Lck is 
recruited to the receptor complex via its interactions with the CD4 and CD8 co-receptors. 
Here Lck clusters together and is believed to trans-autophosphorylate Y394 in its 
activation loop.  Now a fully activated kinase, Lck phosphorylates specific motifs on co-
receptors CD3, TCRζ, and the kinase Zap70 that eventually culminate in T-cell 
activation.  
   
  Cdk2 
Cdk2 is a 298 amino acid serine/ threonine kinase that is essential for proper cell 
cycle progression (reviewed in (128) .  Structurally simple, much like most members of 
the cyclin-dependent kinase family, Cdk2 is made up of a kinase domain without any 
flanking regulatory subunits (129).  Cdk2 kinase activity and substrate specificity 
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however are regulated by the coordinated association with the Cyclin E and Cyclin A 
proteins. Cyclins, which are systematically expressed and degraded throughout the cell 
cycle, bind to Cdk2 and stabilize it in an activatable conformation. Cdk2 can then be 
phosphorylated by CAK (cdk activating kinase, also known as Cdk7/Cyclin H) on T160 
in its activation loop to become an active kinase.  Subsequently, depending upon the 
cyclin with which it is associated, Cdk2 is able to phosphorylate its specific set of 
substrates.  When bound to Cyclin E, Cdk2 substrates include Rb, p27, NPAT, and 
Cyclin E itself.  Phosphorylation of these proteins promotes the initiation of DNA 
replication and the G1/S cell cycle transition.  In contrast, when bound to Cyclin A, Cdk2 
phosphorylates Cdc6, HIRA, Skp1 and Cdc20.  This activity in turn, prevents the re-
replication of the genome and promotes the S/G2 cell cycle transition.  
   
 JNK1α1 
JNK1 belongs to a group of kinases that has been implicated in multiple cellular 
processes such as cell survival, proliferation, embryonic development, T cell activation 
and differentiation (reviewed in (130).   Activated by environmental stress and 
inflammatory cytokines, the JNK group of kinases is encoded by three genes that produce 
ten isoforms due to alternative splicing.  Splice variants differ in their C-terminal 
extension length and substrate binding motif.  This produces ten substrate specific 
isoforms that are either 46 or 54 kDa.  The JNK isoform studied in this work is JNK1α1 
(JNK1 gene; α substrate motif; 1 short C-terminus).  Activation of JNK is carried out by 
the phosphorylation of the TPY motif in its activation loop by MKK4 and MKK7.  
Activated JNK dimerizes and translocates to the nucleus where it phosphorylates the 
 39
transcription factors c-Jun, JunB, JunC, ATF2, and NFAT4.  These events then result in 
altered gene expression allowing the cell to adjust to its new environment.  The structure 
of JNK is relatively simple with no large defined regulatory domains flanking the kinase 
core much like Cdk2.  However, according to the JNK3 crystal structure, the JNK group 
differs in that they contain an extensive C-terminal region that wraps around the kinase 
domain interacting with portions of the αE-helix and the entire αC-helix (131).  Another 
structural feature that distinguishes the JNK group is the presence of two additional anti-
parallel β-sheets that precede motif I, which help to form a β−sandwich within the N-
terminal lobe.  These added structural features no doubt provide JNK with added stability 
and may account for why JNK has not been shown to be an Hsp90 client.  
 
Protein Kinase Interactions with the Hsp90 Chaperone Machine 
As previously explained, protein kinases are highly involved in initiating and 
regulating almost every cellular process in eukaryotic cells, and many of these kinases are 
dependent upon the Hsp90 chaperone machine to function properly.  Despite its being 
over a decade since discovering the relationship between kinases and Hsp90, the basis by 
which certain protein kinases are recognized, recruited, and folded by Hsp90 is still not 
completely understood.  
What is understood about the recognition of kinases by Hsp90 and Cdc37, is that 
they predominantly interact with the catalytic domain of each client kinase.  The specifics 
of their interactions, however remain a mystery.  Deletion mutagenesis of the protein 
kinases Akt and PDK1 initially led to the hypothesis that motifs IV-VIII were only 
needed for interaction with Hsp90 (132, 133).  While this data indicated that motifs IV-
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VIII were necessary for interaction with Hsp90, it did not indicate if this region was 
sufficient for Hsp90 interaction.  This question was then addressed by our group, using 
deletion mutagenesis and puromycin-treated polyribosome pop-off experiments to study 
the interactions of both Hsp90 and Cdc37 with Lck and the heme-regulated eIF2α kinase, 
HRI (108).  This work subsequently demonstrated that motifs V-VIII are not sufficient 
for Hsp90 and Cdc37 binding when expressed by themselves, but are indeed necessary 
when expressed in a construct containing either a complete N-terminal or C-terminal 
kinase lobe. 
Our data suggested that since motifs V-VIII span both the NL and CL and do not 
form a stable multilayered structure, that Hsp90 and Cdc37 do not recognize unstructured 
polypeptides containing little to no tertiary structure (108).  If Hsp90 and/or Cdc37 did 
recognize this unstructured polypeptide it would then suggest that recognition is based on 
amino acid sequence.  This is most unlikely since the amino acid sequence of these 
structural motifs is not highly conserved among client kinases and may even contain the 
insertion of regulatory domains between the NL and CL, such as found in HRI.  Thus, 
this indicates that a complete lobe (either NL or CL) must be present along with motifs 
V-VIII, in order for there to be enough tertiary structure and/or domain stability for 
Hsp90 to recognize and bind the protein kinase construct. Thus, these observations have 
led to the hypothesis that Hsp90 and Cdc37 binding is driven by tertiary structure 
recognition.   
The subsequent chapters in this thesis primarily are focused on experiments 
carried out to characterize the interactions between Hsp90/Cdc37 and protein kinases: the 
molecular basis of kinase recognition by Hsp90 and Cdc37.  As well as, why are some 
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protein kinases clients of Hsp90 and Cd37 while others are not? And structurally, what 
might be the difference between these types of kinase?  
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CHAPTER II 
Definition of Protein Kinase Sequence Motifs that Trigger High Affinity Binding 
of Hsp90 and Cdc37 
Introduction 
 In vivo, Hsp90 function is essential for the biogenesis and support of numerous 
cellular proteins that regulate signal transduction, including transcription factors, protein 
kinases, and a wide variety  of proteins, such as nitric oxide synthase and telomerase 
[reviewed in (15, 134, 135)].  Despite over a decade of intense study, the basis for 
Hsp90’s recognition of its diverse clients remains one of the primary mysteries in the 
field.  Studies using site-directed and deletion mutagenesis (132, 133, 136-140) have 
identified potential sites within steroid hormone receptors and protein kinases that may be 
recognized by Hsp90.   However, while a recent study has indicted that point mutations 
generated in the Cdk4 kinase (141) affect its interaction with Hsp90, no common 
primary, secondary and/or tertiary structural motifs have been defined that may be 
responsible for Hsp90-cleint recognition.  
 Hsp90 functions in conjunction with a coterie of non-client co-chaperone partners 
(reviewed in (15, 134, 135)).  Current models suggest that co-chaperones may confer 
specificity to Hsp90 facilitated protein folding by also interacting with client targets (136, 
142, 143).  Cdc37 is one such Hsp90 co-chaperone that interacts with immature forms of 
Hsp90-dependent kinases (reviewed in (96)).   The biochemical activity of Cdc37 is 
essential for Hsp90-mediated support of kinase function [e.g., (106, 111, 125, 144, 145)].   
 In vitro, Cdc37 exhibits a “passive” chaperone activity similar to that of Hsp90.  
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Cdc37 has been shown to prevent the aggregation of denatured protein, while also being 
able to maintain the protein in a state that is competent  to refold with no requirement for 
input of energy from ATP hydrolysis (144).  Furthermore, the domain structure of Cdc37 
has been determined, and its kinase-binding and Hsp90-binding activities have been 
mapped to its N-terminal and middle domains, respectively (106, 110, 146), and we  have 
demonstrated that phosphorylation of Cdc37 on Ser13 by CK II is required for the ability 
of Cdc37 to bind protein kinases (147).  However, while the specific basis for the 
recognition of protein kinases by Cdc37 is unknown, recent studies have mapped the 
recognition motif to the N-terminal lobe of the catalytic domain of protein kinases (108, 
126, 141). 
 Hsp90 inhibitors have aided studies into the mechanisms underlying the function 
of Hsp90 and its co-chaperones (reviewed in (15, 134, 135)).  Hsp90's N-terminal 
nucleotide binding domain is the site of action for the Hsp90 inhibitor geldanamycin (37, 
38, 148), while its C-terminal domain contains a binding site for novobiocin, which also 
inhibits Hsp90 function (66-68, 149).  Analyses with these compounds, with nucleotides 
and nucleotide analogs, and with site-directed mutants that alter Hsp90’s ATP binding 
and/or ATPase activity have revealed that Hsp90 function is regulated via the binding 
and hydrolysis of ATP, which modulates the switching of Hsp90 between at least three 
alternative conformations (15, 68, 134, 135).  In the presence of geldanamycin, Hsp90 
binds weakly to client kinases in a salt-labile fashion (106-108).  These aberrant Hsp90 
heterocomplexes indicate that nucleotide-modulation of conformational switching is 
required to generate high affinity interactions of Hsp90 and Cdc37 with protein kinases 
(106-108).  Like geldanamycin, the anion molybdate inhibits Hsp90 function.  However, 
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in contrast to geldanamycin this inhibition reflects the ability of molybdate to "lock" or 
freeze Hsp90-kinase complexes in high-affinity salt-stable complexes (106-108).  Thus, 
molybdate causes the accumulation of Hsp90 complexes containing the Hsp90 co-
chaperones p23, Cdc37 and an assortment of other "late" complex components, such as 
TPR motif-containing immunophilins (46, 48, 63, 90, 106-108, 150, 151).  However, 
while molybdate stabilizes the normally labile interaction of Hsp90 with steroid hormone 
receptor clients (48, 107, 108), Hsp90's interactions with kinase clients are stable to high 
salt concentrations independent of molybdate freezing (48, 106-108).  Thus, we have 
utilized the ability of kinase constructs to trigger molybdate-independent, high-affinity, 
salt-stable interactions with Hsp90 and Cdc37 to define motifs recognized by these 
chaperones (108). 
 In this report, we have systematically deleted secondary structural elements from 
the catalytic domain of the Hsp90-dependent Src-family protein tyrosine kinase Lck to 
increase the resolution of motifs recognized by Hsp90 and Cdc37.  The data confirm that 
Cdc37 recognizes structures or sequences present in the N-terminal lobe of the kinase’s 
catalytic domain.  Furthermore, the motifs within the N-terminal and C-terminal lobes of 
the catalytic domain that are required to trigger nucleotide-dependent conformational 
switching of Hsp90 and molybdate-independent high affinity binding of Hsp90 and 
Cdc37 to kinase constructs overlap at the junction of the two subdomains. 
 
Experimental Procedures 
Plasmids.  The coding sequences for protein domains and sub-domains were cloned by 
PCR into a modified pSP64T plasmid (152) as previously described (108, 153, 154).  N-
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terminally His-tagged versions of each domain were constructed.  Sequences represented: 
the Lck NT-terminal domains (NT-SH2-SH3: residues 1-243); catalytic domain (Cat: 
residues 228-498); the N-terminal lobe (NL: residues 228-316) of the catalytic domain of 
Lck plus the linker region between the lobes (NL-linker: residues 228-336); the N-lobe of 
the catalytic domain (NL: residues 228-316); the C-terminal lobe (CL) of the catalytic 
domain of Lck plus the linker between the two lobes (linker-CL: residues 317-498); the 
C-terminal lobe of the catalytic domain containing motifs (123) VIa-XI (CL: residues 
336-498); the NL through conserved  kinase   motifs VIII (NL-APE: residues 228-410);  
the NL through conserved  kinase   motifs VII (NL-β7/8: residues 228-384); the NL 
through conserved  kinase   motifs VIb  (NL-β7: residues 228-375); the NL through 
conserved  kinase   motifs VIa and the β6 sheet region (NL- αE-Cap: residues 228-361); 
the NL through conserved  kinase   motifs VIa  (NL-αE: residues 228-355); the regions 
of Lck’s catalytic domain encompassing kinase motif II through the CL (β3-CL: residues 
261-498); the regions of Lck’s catalytic domain encompassing kinase motif III through 
the CL (αC-CL: residues 276-498); the regions of Lck’s catalytic domain encompassing 
kinase motif IV through the CL (β4-CL: residues 294-498); and the regions of Lck’s 
catalytic domain encompassing kinase motifs IV-VIb (αC-β7: residues 276-375).  These 
dissections are represented graphically in Fig. 11. 
 
Co-immunoprecipitations of chaperones with His-tagged kinase constructs.  Lck 
constructs were cloned via NcoI/EcoRI into a modified pSP64T plasmid that coded for an 
N-terminal His6-tag. Using a no DNA blank as control for non-specific binding (NS), 
each construct was synthesized and radiolabeled with [35S]-Met by coupled 
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transcription/translation in 60 μl of nuclease-treated rabbit reticulocyte lysate (TnT,  
Promega) for 24 minutes at 300 C.  Each sample was then split into two (30 μl) aliquots, 
supplemented with either 0.5 μl of 1 M sodium molybdate (final concentration 17 mM) 
or deionized water, and then incubated for another 1 min.  All samples were then 
immediately placed on ice, clarified and immunoabsorbed with 25 μl of anti-His5 
antibody (Qiagen) bound to anti-mouse resin for 1 hour at 40 C (108).  Immunoresins 
were then washed once with P50T (10 mM Pipes (pH 7.2), 50 mM NaCl, and 0.5% 
Tween-20), three times with P500T (same as P50T except with 500 mM NaCl), and again 
with P50T.  No NaMoO4 was present in the wash buffers.  Finally, the samples were 
boiled in SDS sample buffer, separated on SDS-PAGE, transferred to PVDF membrane, 
and blotted for both endogenous Hsp90 and Cdc37 (108). 
 To load approximately equal molar amounts of each translation product, a portion 
of each TnT reaction was spotted on a piece of filter paper, and precipitated with 10 % 
trichloroacetic acid.  After boiling the filters in 5% trichloroacetic acid, the filters were 
washed sequentially with ethanol, and acetone, and then dried.  The filters were 
subsequently bleached with 15% hydrogen peroxide, dried and counted in a scintillation 
counter.  Equivalent molar amounts of samples were loaded from SDS-elution of resins 
based on the amount of [35S]-Met incorporated into protein construct in each TnT 
reaction and the number of methionine residues present in each construct.  Samples were 
separated by SDS-PAGE, and transferred to PVDF membrane for Western blotting and 
autoradiography.  Membranes were: stained lightly with Coomassie blue to visualize 
protein patterns and the molecular weight markers; dried and exposed to film to 
determine presence and pattern of radioactively labeled protein bands; and then cut 
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according to molecular weight markers for probing with the appropriate anti-chaperone 
antibodies.  Immunoadsorption of each target kinase construct was confirmed by 
autoradiography (not shown in the figures). 
 
Results 
Characterization of the interactions of Lck’s subdomains with Hsp90 and Cdc37.  
While Hsp90 and Cdc37 recognize and interact with the catalytic domain of protein 
kinases (99, 106, 111, 132, 133, 155-157), we have recently reported that Hsp90 also 
interacts with the N-terminal heme-binding domain of the heme-regulated eIF2α kinase, 
HRI (108).   While the kinase domains of Src-family kinases retain the ability to bind 
Hsp90, the possibility that Hsp90 may have additional interactions with the N-terminal 
domains of this kinase family (i.e., the unique N-terminal,  SH3 and SH2 domains) has 
not been investigated.   Therefore, N-terminally His-tagged full length (fl) Lck, the N-
terminal domains of Lck (NT-SH3-SH2), the Lck kinase catalytic domain (Cat) and the 
N-terminal lobe (NL) and C-terminal lobe of the catalytic domain that contained the 
sequences which links the two lobes (linker-CL) were cloned and expressed by coupled 
transcriptional/ translation in nuclease-treated reticulocyte lysate.  The domains were then 
immunoadsorbed with anti-His-tag antibodies and analyzed by SDS-PAGE and Western 
blotting for co-adsorbing chaperones.  Consistent with previous findings (108), full 
length Lck and Lck’s catalytic domain formed salt-stable complexes with Hsp90 and 
Cdc37 independent of the presence of molybdate (Fig.  8).  Hsp90 and Cdc37 also co-
adsorbed with the NL construct of Lck, but molybdate was required to stabilize their 
interactions.  Hsp90, but not Cdc37, interacted with the CL-linker construct of Lck and  
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Fig. 8.  Interaction of Hsp90 and Cdc37 with domain and subdomain constructs of 
Lck. 35S-Labeled His-tagged Lck constructs (full-length (fl) Lck, the N-terminal domains 
of Lck (NT-SH3-SH2), the Lck kinase catalytic domain (Cat), and the NL and CL-linker 
constructs) were synthesized in reticulocyte lysate for 25 min at 30 °C, followed by 
immunoadsorption to anti-His tag antibody resin in the presence or absence of 17 mM 
molybdate. Lysate containing no template (NS, control) was immunoadsorbed as a 
control for nonspecific binding of proteins to the immunoresin. The samples were washed 
and analyzed by Western blotting for the co-adsorption of Hsp90 and Cdc37 as described 
under "Experimental Procedures." Top panel, Western blotted with anti-Hsp90; bottom 
panel, Western blotted with anti-Cdc37 antibodies. 
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molybdate was also required to stabilize this interaction to washing with high salt buffer.  
No Hsp90 or Cdc37 was found to coadsorb with the NT-domains of Lck (NT-SH3-SH2) 
in the presence or absence of molybdate.  Thus, the interaction of Hsp90 and Cdc37 with 
Lck was confined to its catalytic domain, and, as we have previously observed, the 
interaction of Cdc37 was localized to the NL of Lck (108). 
Definition of the minimal motifs within the C-lobe of Lck’s catalytic domain 
required for molybdate-independent high-affinity binding of Hsp90 and Cdc37.  To 
further delineate the kinase segments that interacted with Hsp90 and Cdc37, we utilized 
the crystal structure of Lck’s kinase domain as a guide to express constructs from which 
conserved kinase sequence motifs were deleted from the C-terminal lobe of the kinase 
(Figure 9).  The Lck constructs containing the NL and deletions that terminated the 
catalytic domain just after the “APE-box” (motif VIII, N-APE), the conserved DFG 
residues (motif VII, NL-β7/8) and the conserved  HRDL(K/R)xxN residues (motif VIb, 
NL-β7) formed complexes with Hsp90 and Cdc37 that were stable in high salt in the 
absence of molybdate, and the binding occurred at levels that were nearly equivalent to 
the binding of the catalytic domain (Fig. 9A).   The Lck construct that contained the NL 
and sequences from the linker region terminating with the α-D-helix that connects the 
two kinase lobes (motif V, NL-linker) showed a very weak salt stable interaction with 
Hsp90 and Cdc37, which was markedly enhance in the presence of molybdate.  While 
again as shown in Figure 8, Hsp90 and Cdc37 co-adsorbed with the NL, but only in the 
presence of molybdate. 
To more finely characterize sequences within the C-terminal kinase lobe of Lck 
that were required to trigger the high affinity binding of Hsp90 and Cdc37, two more  
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Fig. 9.  Interaction of Hsp90 and Cdc37 with domain and subdomain constructs of 
Lck catalytic domain containing deletions of CL kinase motifs. (A) 35S-labeled His-
tagged Lck constructs (Lck catalytic domain (Cat), NL-APE, NL-β7/8, NL- β7, and NL-
linker) were synthesized in reticulocyte lysate for 25 min at 30 °C, followed by 
immunoadsorption to anti-His tag antibody resin in the presence or absence of 17 mM 
molybdate. (B) 35S-labeled His-tagged Lck constructs (Lck catalytic domain (Cat), NL-
 β7, NL-αE-Cap, and NL-αE) were synthesized in reticulocyte lysate for 25 min at 30 
°C, followed by immunoadsorption to anti-His tag antibody resin in the presence or 
absence of 17 mM molybdate. Lysate containing no template (NS, control) was 
immunoadsorbed as a control for nonspecific binding of proteins to the immunoresin. 
The samples were washed and analyzed by Western blotting for the co-adsorption of 
Hsp90 and Cdc37 as described under "Experimental Procedures."  
 
 
 
 
 
 51
constructs containing the NL and a portion of the CL were constructed:  an NL with a 
deletion terminating prior to the catalytic Asp residue contained in motif VIb (NL-αE-
Cap); and an NL with a deletion terminating at the end of the αE-helix which lacks the 
three amino acids that cap the C-terminal end of this helix [equivalent to the β-6 sheet in 
the nomenclature for the cAMP-activated protein kinase (123)] and likely stabilizes its 
structure (NL-αE).  The NL-αE-Cap construct showed molybdate-independent salt-
stabile interactions with Hsp90 and Cdc37 that were reduced by approximately 50% 
compared to the Lck catalytic domain and the NL-β7 construct (Fig. 9B).  However, in 
the presence of molybdate, the binding of Hsp90 and Cdc37 to the NL-αE-Cap construct 
was nearly equivalent to the binding of the proteins to the NL-β7 construct.  In contrast, 
the interaction of Hsp90 and Cdc37 with the NL-αE construct was scarcely detectable in 
the absence of molybdate, and was markedly decreased even in the presence of 
molybdate when compared to the NL-αE-Cap construct.   Thus, it seems that the six 
amino acid residues just past the end of the α-E-helix in the C-terminal lobe of Lck’s 
catalytic domain appear to be required to trigger Hsp90 to adopt its high affinity binding 
conformation.  
Definition of the minimal motifs within the N-lobe of Lck’s catalytic domain required for 
molybdate-independent high-affinity binding of Hsp90 and Cdc37-    Similarly, to more 
clearly characterize sequences within the N-terminal kinase lobe of Lck that were 
required to trigger the high affinity binding of Hsp90 and Cdc37, we prepared constructs 
of Lck’s catalytic domain that contained the complete C-terminal kinase lobe (CL) from 
which conserved kinase sequence motifs were deleted from the N-terminal lobe.   
Constructs of the catalytic domain were made from which:  the β1 and β2  
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Fig.10.  Interaction of Hsp90 and Cdc37 with domain and subdomain constructs of 
Lck catalytic domain containing deletions of NL and CL kinase motifs. (A) 35S-
labeled His-tagged Lck constructs (Lck catalytic domain (Cat), β3-CL, αC-CL, β4-CL, 
linker-CL, and CL) were synthesized in reticulocyte lysate for 25 min at 30 °C, followed 
by immunoadsorption to anti-His tag antibody resin in the presence  or absence of 17 mM 
molybdate. (B) 35S-labeled His-tagged Lck constructs (Lck catalytic domain (Cat), αC-
CL, NL-β7, and αC-β7) were synthesized in reticulocyte lysate for 25 min at 30 °C, 
followed by immunoadsorption to anti-His tag antibody resin in the presence or absence 
of 17 mM molybdate. Lysate containing no template (NS, control) was immunoadsorbed 
as a control for nonspecific binding of proteins to the immunoresin. The samples were 
washed and analyzed by western blotting for the co-adsorption of Hsp90 and Cdc37 as 
described under "Experimental Procedures."  
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sheets (motif I) were deleted (β3-CL); the  β1, β2, and β3 three sheets (motifs I-II) were 
deleted (αC-CL); the region from the β1 sheet through the α-C-helix was deleted (motifs 
I-III, β4-CL); the region from the β1sheet through the β5 sheet was deleted (motifs I- IV, 
linker-CL) and the region from the β1 sheet through the connecting strand including the 
α-D-helix was deleted (motifs I-V, CL).  Of these constructs, the β3-CL and the αC-CL 
constructs showed molybdate-independent salt-stable interactions with Hsp90 and Cdc37 
that were reduced by approximately 50% compared to the Lck catalytic domain (Fig. 
10A).  The β4-CL, linker-CL and the CL constructs showed no interaction with Hsp90 or 
Cdc37 in the absence of molybdate.  In the presence of molybdate the β4-CL and the 
linker-CL constructs were found to have a very weak interaction with Hsp90, but no 
interaction with Cdc37.  The CL construct showed no interaction with either Hsp90 or 
Cdc37 in the presence of molybdate.  Thus, the presence of the α-C-helix within in the 
N-lobe of the Lck kinase was required for the binding of Cdc37.  In addition the region of 
Lck that connects the N- and C-lobes of the catalytic domain is required for minimal 
recognition by Hsp90, and the presence of molybdate is required to stabilize this 
interaction. 
Determination of the Effect of the Region that Links the N- and C-terminal Kinase 
Lobes on Hsp90/Cdc37 Binding.  To test the hypothesis that the borders required for 
Hsp90 and Cdc37 that were identified in the experiments shown in Figures 9 and 10A 
defined the minimal Hsp90/Cdc37 interacting motif a construct of Lck was made that 
contained the region between the α-C-helix and β7 sheets (motifs III-VIb, αC-β7).  
While the αC-CL and the NL-β7 constructs demonstrated molybdate-independent salt-
stable binding to Hsp90 and Cdc37, albeit at a somewhat reduced level,  no interaction of 
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the αC-β7 construct was observed with Hsp90 and Cdc37, even in the presence of 
molybdate (Fig. 10B).   
 
Discussion 
 The work presented here further defines the motifs or structures that are required 
for recognition of kinases by Hsp90 and Cdc37, as defined by molybdate-stabilized 
binding of Hsp90 and Cdc37 to kinase constructs, and for triggering conformational 
switching of Hsp90, as defined by salt-stable binding of Hsp90 and Cdc37 to kinase 
constructs that occurs independent of the presence of molybdate.  Data presented here 
indicate that the Hsp90-Cdc37 heterocomplex binds to kinase molecules primarily via the 
specific recognition of kinase motifs or structures present in both the N-terminal and C-
terminal lobes of the kinase catalytic domain of Lck.   This is consistent with our 
previous work that demonstrate that multiple kinase motifs present within both lobes of 
kinases are required to trigger molybdate-independent high-affinity binding of Hsp90 and 
Cdc37 to protein kinases (108).  
 The linker region that connects the N- and C-terminal lobes of the Lck kinase 
appears to play a critical role for Hsp90 binding.  The NL-linker and the linker-CL both 
interacted with Hsp90 albeit with reduced affinity.  Stabilization of this interaction of 
Hsp90 with these constructs by the addition of molybdate markedly increased the level of 
hsp90 binding indicating that the minimal constructs were deficient in triggering Hsp90 
conformational switching.   The NL and CL constructs that lacked the linker region failed 
to bind Hsp90 in the absence of molybdate, and only the NL exhibited any detectable 
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interaction with Hsp90 (~5% compared to the catalytic domain control) in the presence of 
molybdate.    
 Results presented here together with previously published data (108, 141) localize 
the Cdc37 recognition motif to the αC-helix and the αC-β4 loop motif in the N-lobe of 
the catalytic domain of protein kinases.  Cdc37 did not interact with the linker-CL Lck 
construct, while Hsp90 bound the construct.  Lck constructs of the CL containing 
deletions of the β1, β2 and β3 sheets within the N-lobe stably bound Cdc37 and Hsp90 in 
a molybdate-independent manner, although the level was reduced by ~50% compare to 
the intact catalytic lobe.   Deletion of the αC-helix negated the interaction of Cdc37, but 
not Hsp90 with Lck constructs containing the complete CL.  Previous work investigating 
the interaction of Cdc37 with Cdk4 constructs fused to the C-terminus of GST indicated 
that GST-Cdk4 constructs containing the NL of Cdk4 through the αC-helix and residues 
within the loop between the αC-helix and β4 sheet bound Hsp90 and Cdc37 (141).  
Deletion of residues in the loop caused a marked reduction in Hsp90/Cdc37 binding.  
Thus, the results of the two studies intersect at the region of the αC-helix-β4 loop. 
 The presence of a β-sheet structure appears be necessary for recognition of the N-
lobe of kinase catalytic domains by Hsp90 and/ or Cdc37.   However, our results differ 
from those obtained in the studies utilizing the Cdk4 kinase (141).   Single layered β-
sheet structures are not stable, as the hydrophobic face of the sheet in solution would be 
exposed to water.  Thus, β-sheet structures must interact with an additional “layer” for 
their structure to be stabilized.  The crystal structure of Cdk2 [the protein kinase with the 
greatest sequence similarity to Cdk4 that has been crystallized  
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(129)] suggests that there is no interaction between the hydrophobic face of the first three 
strands of β-sheet in the kinase N-lobe and the hydrophobic face of the αC-helix.  
However, the crystal structures of the inactive conformations of c-Src and Hck indicate 
that their β4/5-sheets may be stabilized through interactions with conserved hydrophobic 
residues in the linker region that connects the SH2 domain to the catalytic domain (158-
161).  Thus, Hsp90 and/ or Cdc37 may also act to stabilize the β-sheet structure within 
the N-lobe during folding in the absence of other interactions that stabilize the domain in 
the mature structure.   
Thus, the results obtained in this study utilizing the Lck kinase catalytic domain 
compared to the results obtained with Cdk4 kinase suggest that there are subtle 
differences between protein kinase families relative to how their five stranded β-sheet 
layers are stabilized during kinase folding, in addition to how they are packed onto and 
influence the orientation of the αC-helix.  Subtlies in the topology of N-lobe β-sheet 
layers likely account for the observation that mutation of Gly15 in the P-loop in the Cdk4 
kinase or deletion of the first two strands of the β-sheet markedly decreases the binding 
of Cdc37, while deletion of the entire P-loop structure of the Lck catalytic domain has no 
effect on the binding of Hsp90 and Cdc37 to the β3-CL Lck construct.  Since Cdc37 
functions to foster the active conformation of protein kinases, the interactions of 
Hsp90/Cdc37 with components of the N-lobe may function to stabilize the β-sheet 
structure in a manner that facilitates Cdc37-induced rotation of the αC-helix.  The crystal 
structures of the inactive conformations of Cdk2, Src and Hck indicate that the catalytic 
Glu in the αC-helix lies on the outer surface of the proteins and that the helix must be 
rotated to properly position of the Glu within the catalytic pocket (129, 158-161).  
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However, the crystal structures suggest that interactions between residues within the αC-
helix and β4-loop with residues present in the C-lobe would sterically impede or prevent 
such a rotation from occurring spontaneously. 
Our data indicate that the minimal kinase structure that is required to trigger 
molybdate-independent high-affinity binding of Hsp90/Cdc37 is one complete lobe of the 
protein kinase’s catalytic domain, the connecting linker and a portion of the second lobe.  
For the constructs containing the complete C-lobe of Lck, the minimum N-lobe structure 
consists of the αC-helix and the β4/5-sheets, while for the complete N-lobe the minimum 
C-lobe structure consists of the αE-helix and the residues that cap its structure at its C-
terminus (equivalent in kinase nomenclature to the β6 strand of the cAMP-activated 
protein kinase (123)).  Although it is noteworthy that inclusion of catalytic residues that 
follow the β-7 sheet in the C-lobe restore nearly wild-type binding of Hsp90 and Cdc37 
to construct of Lck’s NL.  However, the combination of these minimum structures, the 
construct containing the α-C-helix through the αE-helix-cap (αC-β7) does not bind 
Hsp90 or Cdc37.   This finding is consistent with observation that substantial or partial 
folding of client proteins appears to occur prior to recruitment of Hsp90 to the client. 
Thus, we have further defined the minimum motifs within protein kinase clients that are 
recognized and "trigger" the Hsp90 chaperone machine to undergo its nucleotide-
mediated conformational switching.  Furthermore, the results indicate that the presence of 
the minimal Cdc37 recognition motif is not sufficient to stabilize the binding of Cdc37 to 
the construct in the absence of a stabile interaction of the construct with Hsp90.  
The localization of this “switching motif / conformational trigger” is also 
noteworthy as the minimal structures within the two domains intersect at the region that 
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makes up the “hinge” between the two lobes of the kinase (162).  With the exception of 
the “activation-loop”, comparison of crystal structures of inactive and active 
conformations of protein kinases indicate that the position of residues contained within 
the C-terminal lobe of protein kinases are nearly superimposable.  Additionally, this 
analysis of kinase structures indicates that the αC-helix-β4 loop and the peptide strand 
connecting the N-terminal and C-terminal catalytic lobes act as a key region for global 
changes in kinase conformation that regulate the activation and activity of protein kinases 
(162).  Our data suggest that these kinase motifs are critical for the binding of Hsp90 and 
Cdc37 to kinases.  Furthermore, the superimposition of kinase structures indicate that the 
αC-helix of the N-lobe is rather randomly disposed, but with structural elements meeting 
at the point of the "hinge" (162).  This region is located where the αE-helix intersects 
with the loop between the αC-helix and the β4-strand of the N-lobe and the linker region 
between the two kinase lobes.  At this point the β7/8-strands, which contain the catalytic 
kinase residues present in the C-lobe, loop over the αE-helix and pass between the loop 
connecting the αC-helix and β4-strand and the strand that connects the two kinase lobes 
(Fig. 14A).  Premature packing of the αC-helix-β4 loop and the peptide strand 
connecting the two catalytic lobes onto the αE-helix would preclude the proper 
positioning of the β7/8-strands.  Thus, the Hsp90 chaperone complex may function to 
allow the independent folding of the two catalytic subdomains of protein kinase prior to 
their subsequent packing into an active or activatable structure.  This hypothesis would be 
consistent with the apparent requirement for at least one full kinase subdomain and 
additional sequences within the second subdomain, and that the minimal motifs required 
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for triggering high affinity binding of Hsp90 intersect at the point at which the two 
subdomains interact.   
Comparisons of crystal structures indicate that twisting motions about the hinge 
affect the relative position of the N-terminal kinase lobe and the αC-helix.  This motion 
affects the position of the conserved catalytic Lys and Glu residues relative to the 
catalytic residues present in the C-terminal lobe (162), such that  small perturbations of 
these structural elements have significant effects on kinase conformation, and kinase 
activity (162).  Furthermore, in the absence of bound nucleotide, the hydrophobic pocket 
that is occupied by the adenine ring may collapse upon exposure of the ATP binding 
pocket to water.  Thus, the Hsp90 chaperone machinery may function to correct structural 
perturbations that render the catalytic domain inactive by physically separating the two 
subdomains of a kinase’s catalytic lobe allowing them to refold independently.  
Concurrently, Cdc37 might function to stabilize the orientation of the catalytic Glu 
residue in the αC-helix relative to the position of the catalytic Lys.  Subsequently, the 
kinase subdomains would then be released from the Hsp90/Cdc37 complex and allowed 
to interact (repack) into an active or activatable conformation that is capable of binding 
ATP. 
What mechanisms then govern Hsp90's recognition of protein structures and its 
switching from low affinity to high affinity binding?  The data of Pratt and co-workers  
(137) suggest a model of the ligand-binding domain (LBD) of the glucocorticoid receptor 
acting as a “hinged pocket”.  They propose that Hsp90 recognizes α-helical structures 
that interact at the interface between the two subdomains of the LBD, and that sequences  
 
 60
 
 
 
Fig. 11.  Summary of protein kinase constructs used for analysis of Hsp90 and Cdc37 
binding to Lck constructs. The domain architecture of the Lck kinase is indicated at the 
top of the diagram. The numbers above the lines indicate the amino acids residues that 
flank: the unique N-terminal domain of Lck (NT), SH2 and SH3 domains, the NL of Lck, 
the linker region between the NL and CL of Lck, the CL of Lck, and the C-terminal tail 
of Lck. The Roman numerals below the line indicate the locations of conserved kinase 
motifs I-XI. The lower lines indicate the amino acid residues present in each of the 
domain and subdomain constructs studied in this report and where the constructs begin 
and terminate with the abbreviation used to refer to each construct indicated to the right 
of each line. The chart to the right summarizes the binding of Hsp90 and Cdc37 to the 
constructs in the absence or presence of molybdate: ++, binding equivalent or nearly 
equivalent to the catalytic domain; +, binding reduced by ~50% relative to the catalytic 
domain; +/-, binding less than 10% of that of the catalytic domain; -, no detectable 
binding 
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Fig. 12. Depiction of Lck deletion mutant constructs. A different color is shown for 
each segment of Lck deleted in respect to Fig. 11: residues 228-261, red; residues 262-
276, yellow; residues 277-294, cyan; residues 295-316, magenta; residues 317-336, 
orange; residues 337-355, blue; residues 356-361, green; residues 362-375, redorange; 
residues 376-384, greenblue; residues 385-410, violet; residues 411-498, purple. The 
kinase domain is shown with its ATP binding cleft facing either (A) toward or (B) away 
from the viewer. 
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Fig. 13. Close-up of the αC-helix-β4 loop interface with the αE-helix and the αE-
helix capping motif.  The αC-helix and the β4 loop are shown in cyan and magenta, 
respectively. The αE-helix and the αE-helix capping motif are shown in blue and green, 
respectively.  Deletion sites are designated and labeled black. 
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present in a β-sheet structure function as a hinge between the two subdomains.  This 
interaction of Hsp90 with the LBD is proposed to break the hydrophobic clasp formed by 
the interaction between the two subdomains, allowing hormone to access its ligand 
binding site.  The trypsin sensitivity of the LBD near the β-stranded region suggests that 
its flexibility would allow separation of the two subdomains (137).  Similar to the 
findings reported here, deletion analysis of the LBD (143) indicates that a construct 
containing the complete N-terminal subdomain of the LBD and the β-stranded hinge 
through the first α-helix of the C-terminal portion of the ligand binding subdomain is the 
minimal construct of the glucorocorticoid receptor that binds Hsp90 (Fig. 14B).  
Of further interest is the observation that the two strands of β-sheet that make up 
this proposed hinge are a single layer motif with the sequence 620-LLCFAPDLII-629.   
The side of the sheet facing the ligand binding pocket is composed exclusively of 
hydrophobic amino acids, with the surface of the sheet also having considerable 
hydrophobic character.   The “hole” representing the ligand binding pocket results in both 
sides of the β-sheet being exposed to solvent.  Thermodynamics might favor the collapse 
of the β-sheet structure into the protein’s interior in the absence of hormone occupying its 
binding pocket, considering that this region has been reported to be conformationally 
mobile (137).  Thus, an additional consequence of Hsp90 separating the two subdomains 
of the LBD would be to reposition the β-strands, and allow refolding of the hormone-
binding pocket. 
 The findings of Pratt and co-workers, together with the data presented here 
suggest a common theme for Hsp90 function.  Hsp90 and its associated co-chaperones 
may function to facilitate protein folding by breaking interactions between subdomains 
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within a protein’s structure.  Inspection of the crystal structures of Lck’s kinase domain 
and the GR’s LBD indicate that the structures of the flexible linker regions between the 
N- and C-terminal subdomains of each of these proteins, and the α-helical region that 
follows are strikingly similar (Fig. 14, right panels).  The separation of the subdomains of 
SHRs or protein kinases may function to displace protein structures that impede the 
ability of critical amino acid residues to be properly positioned, or to reposition critical 
amino acids, which would subsequently allow the protein to attain its active or activatable 
(regulatable) conformation: attain a structure capable of binding ATP or hormone, 
respectively.  For the de novo folding of protein kinases, Hsp90 may be required to 
reorient a two-stranded β-sheet structure, subsequently allowing the structure to occupy a 
“hole” formed at the junction between the two catalytic subdomains and for the ATP 
binding pocket to be properly folded.  While for steroid hormone receptors, Hsp90 would 
function to reorient a two-stranded β-sheet structure, removing the structure from a 
“hole” which exists due to the absence of hormone occupying its LBD, subsequently 
allowing the unoccupied steroid hormone binding pocket to reform.  These distinct 
variations between protein kinases and steroid hormone receptors may then account for 
the differences in the characteristics of their interactions with Hsp90.  Whereas the 
catalytic domains of protein kinases can form high-affinity salt-stabile complexes with 
Hsp90 in the absence of molybdate (107, 108), the LBD of steroid hormone receptors 
require molybdate to stabilize Hsp90 binding (89).  Additionally, while Cdc37 is required 
for Hsp90 to form high-affinity complexes with protein kinases and for their productive 
folding, Hsp90 has not been documented to require such a cohort when restoring steroid 
hormone receptor function. 
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Fig. 14.  Diagrams of the Lck kinase catalytic (A) and the glucocorticoid receptor ligand-binding 
domain (B) highlighting structural motifs that have been implicated in their interactions with Hsp90. 
The diagrams of Lck catalytic domain (PDB: 1QPC) and glucocorticoid receptor-LBD (PDB: 1NHC). (A) 
left and center panels, residues 231-275 (the first three β-strands of the Lck catalytic domain) are colored 
gray; residues 276-317 (the αC-helix and β-strands 4/5) are colored green; residues 318-329 (the random 
coil and α-D-helix) are colored cyan; residues 330-336 (the αhelical insert between the αD and αE-helix) 
are colored yellow; residues 337-361 (the αE-helix and its cap) are colored red; residues 362-375 (motif 
VIB containing the β-7 sheet) are colored black; the backbone of residues 376-384 (motif VII containing 
the β-8 sheet) are colored dark blue; and the remainder of the molecule is shown in wire frame mode and 
colored by structure (magenta, α-helix; white, random coil). (B) left and center panels, residues 530-537 
(the α1-helix) and residues 582-587 (a short α-helix between helix 3 and 4 of the glucocorticoid receptor-
LBD that are proposed to be part of the "hydrophobic clamp") are colored green; residue 538-581 (the end 
of the α1-helix through the α3-helix) are colored gray); residues 588-619 (the α4 and α5-helices) are 
colored cyan; residues 620-630 (the two strands of β-sheet in the linker region) are colored black; residues 
631-638 (the α6 helix in the hinge region containing Arg633 shown in stick format) are colored yellow; 
residues 639-659 (the α7-helix) are colored red; the remainder of the C-terminal subdomain is shown in 
wire frame format and colored by structure (magenta, α-helix; yellow, β-sheet; white, random coil). (A)  
and (B), right panels, cartoon diagram of the proposed hinge regions of the kinase domain of Lck and the 
LBD of the glucocorticoid receptor followed by the minimal part of the C-terminal subdomain of each 
molecule that is required for Hsp90 binding colored by structure, with hydrophobic residues colored green. 
(A) left and center panels, open arrows, positions of β7 and β8 strands that must past between the junction 
of the N- and C-terminal kinase subdomains. (A)  and (B), left panel, closed arrow, and center panel, open 
sided box, positions of linker regions between the two subdomains of each protein; curved arrows,indicate 
proposed movement of the subdomains that would be required to reposition the β-sheet structures at the 
interface between the two subdomains of each protein. (B) open arrow, position of the ligand-binding 
pocket behind the two strands of β-sheet. 
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CHAPTER III 
Hsp90 and Cdc37 Interactions with the Protein Kinase Cdk2 
Introduction 
Hsp90 is a 90 kDa ATPase that functions as a molecular chaperone for a multitude of 
signal transduction proteins, which play critical roles in controlling practically every facet 
of a cell’s physiology.  The ability of Hsp90 to function as a chaperone to this wide array 
of signal transduction proteins is due, in part, to the coterie of non-client co-chaperones 
that are components of the Hsp90 heteromeric super-chaperone machine (14, 15, 134, 
135).  In this regard, the Hsp90 co-chaperone Cdc37 is a protein required for the viability 
of eukaryotic cells (96, 97).  Cdc37 carries out a function essential for Hsp90’s ability to 
support the activity of numerous protein kinases, as such Cdc37 is often referred to as the 
“kinase specific co-chaperone” (106, 125, 144, 145).  However, Cdc37 has also been 
found in complexes with the androgen receptor and certain viral reverse transcriptases 
suggesting it likely has a broader set of clients (112, 116). 
 As noted above, protein kinases, which are one of the largest families of signal 
transduction proteins (120), often depend upon Hsp90 to carry out their function.  Hsp90, 
together with Cdc37, interacts with protein kinases to facilitate their proper folding and/ 
or stabilize their structure  (106, 108, 125, 144, 145).  The productive interactions of 
Hsp90 and Cdc37 with protein kinases are known to require the presence of specific 
stuctural motifs within the protein kinase’s bi-lobal structure (108, 163).  Nevertheless, 
despite years of study, the exact manner of recognition of these structural motifs by 
Hsp90 and Cdc37 is still not completely understood. 
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Previous studies carried out by our laboratory, in which defined secondary 
structural elements were deleted from the Lck tyrosine kinase, have identified potential 
structural motifs required for high affinity binding of Hsp90 and Cdc37 to protein kinases 
(108, 163).  However, our findings are at variance with studies done with the cyclin-
dependent kinase, Cdk4 (141).  In that work, the G-box (also known as P-loop) was 
identified as a motif needed for the interaction of Cdk4 with Cdc37, whereas in our Lck 
model the deletion of this motif had no effect on the binding of Cdc37 to Lck.  
Consequently, we have attempted to refine our understanding of Hsp90 and Cdc37 
interactions with protein kinases by studying yet another kinase, the cyclin-dependent 
kinase Cdk2. 
 Cdk2 is a protein kinase that regulates cell cycle progression through the 
coordinated association with specific regulatory proteins, known as cyclins (128).  Upon 
cyclin binding Cdk2 is able to undergo a conformational change that allows its activation 
loop to be phosphorylated on T160 by Cdk-activating kinase (CAK, also known as 
Cdk7/cyclin H) (164).  Activated Cdk2 is then able to phosphorylate downstream effector 
proteins, which in turn help drive DNA replication and eventually S/G2 transition.  
Additionally, Cdk2’s kinase activity can be inhibited by phosphorylation of G-box 
residue Y15 by the bifunctional kinase Wee1 (165-167). 
 Previous genetic and yeast two-hybrid studies have shown that both Hsp90 and 
Cdc37 interact with Cdk2, suggesting that Cdk2 is an Hsp90 client kinase (126).  
Furthermore, it has been shown that Cdc37 interacts with the N-terminal lobe of Cdk2, an 
observation supported by our findings with Lck (108, 163).  However, despite these and 
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other studies no true physical interaction between Cdk2 and Hsp90 or Cdc37 via pull-
down assays has been documented (125). 
 In this report, we demonstrate that Cdk2 indeed physically interacts with Hsp90 
and Cdc37 via pull-down assays and subsequently verify Cdk2 as a client protein kinase 
of the Hsp90/Cdc37 chaperone complex. A series of N-terminal and C-terminal deletions 
of Cdk2 were constructed to further define the structural motifs required to trigger 
molybdate-independent high affinity binding of Hsp90 and Cdc37 to the protein kinase.  
Our results again suggest that the αC-helix of Cdk2 is critical for the recognition of 
protein kinases by Hsp90 and Cdc37. 
 
Experimental Procedures 
Plasmids.  Cdk2 constructs were cloned via NcoI/EcoRI into a modified pSP64T plasmid 
that coded for an N-terminal His6-tag as previously described (108).  N-terminally His-
tagged versions of each domain were constructed.  Sequences represented: full length 
Cdk2 (FL: residues1-298); the N-terminal lobe through structural motif VII (NL-β7: 
residues1-143); the N-terminal lobe through structural motif VI (NL-Cata: residues1-
132); the N-terminal lobe through structural motifs V and part of VI or the uncapped αE 
helix (NL- αE: residues 1-120); the NL (residues 1-82);  structural motif II through the 
CL (β3-CL: residues 19-298); structural motif III through the CL (αC-CL: residues 37-
298); structural motif IV through the CL (β4-CL: residues 63-298).   The plasmid, 
pcDNA3-CycA(wt)-AU5 which encodes for T7 driven Cyclin A with the C-terminal 
epitope tag, AU5 was a generous gift from Dr. Joan Ruderman of Harvard Medical 
School. 
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Synthesis of His-tagged Cdk2. Using a no DNA template as a control for non-specific 
binding, His-tagged Cdk2 was synthesized and radiolabeled with [35S]-Met by coupled 
transcription/translation in 25 μl/ tube of nuclease-treated rabbit reticulocyte lysate (TnT,  
Promega) for 30 minutes at 300 C.   For samples treated with drugs, geldanamycin (GA, 
10 μg/ml final concentration) and dimethylsolfoxide (DMSO) were added prior to 
initiating synthesis.    
 
Synthesis of Cyclin A with Cdk2 in the presence and absence of geldanamycin.  Sp6 
driven His-tagged Cdk2 and T7 driven Cyclin A-AU5 were synthesized separately and 
radiolabeled with [35S]-Met by coupled transcription/translation in nuclease-treated rabbit 
reticulocyte lysate (TnT, Promega) for 30 minutes at 300 C in the presence of either 
10 μg/ml GA or DMSO.  Samples were then combined and mixed accordingly, 20 μl 
each to give a total volume of 40 μl, and incubated at 370 C for another 30 minutes.   
 
Synthesis of His-tagged Cdk2 deletion constructs.  Using a no DNA blank as a control for 
non-specific binding (NS), each construct was synthesized and radiolabeled with [35S]-
Met by coupled transcription/translation in 60 μl of nuclease-treated rabbit reticulocyte 
lysate (TnT,  Promega) for 30 minutes at 300 C.  Each sample was then split into three 
aliquots, two ~27 μl aliquots supplemented with either 0.5 μl of 1 M sodium molybdate 
(final concentration 17 mM) or deionized water, and then incubated for another 1 min.  
The remaining 5-6 μl of TnT lysate was put into 50 μl of SDS-sample buffer and ran on a 
10% SDS-PAGE gel and checked by autoradiography as input controls.   
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Immunoabsorption of synthesized proteins. All immunoabsorption samples were 
immediately placed on ice, clarified by centrifugation with a Fisher 235c microfuge at 40 
C for 5 min, and immunoabsorbed with 25-30 μl of either anti-mouse or anti-rabbit 
immuno-resin coupled with either mouse anti-His5 (Qiagen), mouse non-specific IgG,  
rabbit anti-AU5 (Covance Research), rabbit sc-53 anti-PSTAIRE (Santa Cruz 
Biotechnology), or rabbit non-specific IgG for 1 h at 40 C.  Immunoresins were then 
washed once with P50T (10 mM Pipes (pH 7.2), 50 mM NaCl, and 0.5% Tween-20), two 
times with P500T (same as P50T except with 500 mM NaCl), and again with P50T.  No 
molybdate was present in the wash buffers.  Finally, the samples were boiled in SDS 
sample buffer, separated on an 8% SDS-PAGE gel, transferred to PVDF membrane, and 
blotted for both endogenous Hsp90 and Cdc37 (108). 
 
Cdk2 expression in GA treated K562 cells.  K562 cells were grown in 6-well plates in 
RPMI 1640 media with 10% FBS and 1% antibiotics at 50% confluency. Cells were 
grown in the presence of either DMSO or 0.1 μM GA for 0, 12, 24, or 48 hours, then 
washed once with Hanks’ balanced salts and lysed in lysis buffer: 0.5% Igepal, 20 mM 
Hepes pH 7.4, 100 mM NaCl, 2 mM EGTA, 10 % glycerol, and mammalian protease 
inhibitor cocktail (Sigma).  Lysates were clarified by centrifugation and protein 
concentrations were determined via BCA assay (Pierce).  Samples were then analyzed by 
SDS-PAGE and western blotting with polyclonal anti-Cdk2 (rabbit sc-748, Santa Cruz).   
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Results 
Hsp90 and Cdc37 physically interact with Cdk2- Previous genetic studies have 
suggested that both Hsp90 and Cdc37 interact with Cdk2 (126).  However, no direct 
physical interaction has been documented between Cdk2 and the Hsp90/Cdc37 chaperone 
complex.  Indeed, one of the initial papers describing the interactions of Cdc37 with Cdk 
kinases concluded that Cdc37 did not interact with Cdk2 (125).  Yet, Cdk4, a close 
relative of Cdk2, has been well established as client protein kinase that physically 
interacts with Hsp90 and Cdc37. 
Complexes between Hsp90/Cdc37 and Cdk4 have been isolated from cell 
extracts, as well as reconstituted in vitro utilizing Cdk4 generated by coupled 
transcription/ translation (TnT) in rabbit reticulocyte lysate (125, 141).  Thus, we tested 
whether a physical interaction between Cdk2 and Hsp90/Cdc37 could similarly be 
reconstituted in reticulocyte lysate with newly synthesized Cdk2.  Cdk2 was cloned with 
an N-terminal His-tag and [35S]-labeled His-tagged Cdk2 was synthesized by TnT in 
reticulocyte lysate.  His-tagged Cdk2 was then immunoadsorbed with anti-His antibody 
and the immune pellets were washed at high stringency (buffer containing 0.5 M NaCl).  
Western blot analysis subsequently indicated that both endogenous Hsp90 and Cdc37 
specifically co-absorbed with Cdk2 (Fig. 15A), consistent with results found for Cdk4. 
 Hsp90 inhibitors have aided studies into the mechanisms underlying the function 
of Hsp90 and its co-chaperones.  The N-terminal nucleotide-binding domain of Hsp90 is 
the site of action for the inhibitor geldanamycin.  In the presence of geldanamycin, Hsp90 
is held in an “unlocked” conformation, which binds weakly to protein clients in a salt-
labile fashion (106-108).  To further test whether Cdk2 interacted with Hsp90 and Cdc37 
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in the manner of a protein client, His-tagged Cdk2 was expressed in the presence or 
absence of the Hsp90 inhibitor geldanamycin, immunoadsorbed and analyzed as 
described above.  Again, consistent with the interaction of Hsp90 and Cdc37 with other 
client protein kinases (106-108), Hsp90 and Cdc37 did not form a complex with Cdk2 in 
the presence of geldanamycin that was stable to buffer containing 0.5 M NaCl (Fig. 15B).  
Therefore, these results support the hypothesis that Cdk2 is a client of the Hsp90/Cdc37 
chaperone complex.   
Antibody directed against the αC-helix of Cdk2 disrupts its interactions with 
Hsp90 and Cdc37-   As noted above, in previously published work, it was concluded that 
Hsp90 and Cdc37 did not physically interact with Cdk2 (125).  This work utilized the 
Cdk2-specific sc-53 antibody, which is directed against the amino acid sequence 
PSTAIRE in Cdk2’s αC-helix.  Since this work conflicted with the results described 
above, we tested whether Hsp90 and Cdc37 would co-absorb with newly synthesized 
His-tagged Cdk2 immunoadsorbed from reticulocyte lysate with sc-53, as opposed to 
anti-His-tag antibody.  Western blotting indicated that Hsp90 and Cd37 co-adsorbed with 
His-tagged Cdk2 from reticulocyte lysate with anti-His tag antibody (Fig. 15C).  Again 
this interaction was specific as no Hsp90 or Cdc37 was present in immune pellets 
containing bound mouse non-immune IgG.   
Consistent with previous work, Hsp90 and Cdc37 did not co-absorb with His-
tagged Cdk2 immunoadsorbed with sc-53.  These results suggested that binding of sc-53 
to sequences in the αC-helix prevents Hsp90 and Cdc37 from interacting with Cdk2.  The 
binding of the sc-53 antibody to the αC-helix undoubtedly distorts Cdk2’s conformation, 
and suggests that the αC-helix is recognized by, or is required  
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Fig. 15.  Interaction of Hsp90 and Cdc37 with newly synthesized Cdk2.  His-tagged 
Cdk2 was synthesized and labeled with [35S]-Met in reticulocyte lysate for 30 min at 300 
C, followed by immunoabsorption.  All samples were washed with P50T once, P500T 
twice, and P50T once more.  Samples were then separated by SDS-PAGE and western 
blotted for co-absorbing endogenous Hsp90 and Cdc37, according to “Experimental 
Procedures”.  (A) Using a no DNA blank as a control for non-specific binding, His-
tagged Cdk2 was immunoadsorbed with anti-His5 coupled immunoresin. (B)  Using a no 
DNA blank as a control for non-specific binding, His-tagged Cdk2 was synthesized in the 
presence and absence of geldanamycin (GA) and immunoadsorbed with anti-His5 
coupled immunoresin.  (C) Using rabbit non-immune IgG (rNI) and mouse non-immune 
IgG (mNI) as controls for non-specific interactions, His-tagged Cdk2 was synthesized 
and specifically immunoabsorbed with anti-PSTAIRE (sc-53) and anti-H5 antibodies. 
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to maintain the structure of motifs recognized by Hsp90 and/or Cdc37.  This is result is 
consistent with our previous structural studies utilizing the Lck tyrosine kinase (108, 
163), where Hsp90 and Cdc37 were able to interact with N-terminal deletion constructs 
that contained the αC-helix, but were unable to interact with the deletion constructs that 
were missing the αC-helix in the absence of molybdate.  Together these results suggest 
that the αC-helix may play a critical role in the recognition and interaction of protein 
kinases with Cdc37 and Hsp90. 
Inhibition of Hsp90 destabilizes Cdk2 in K562 cells-  Inhibition of Hsp90 function 
in vivo destabilizes many Hsp90-dependent proteins and accelerates their proteolytic 
breakdown in cells (23).  To further test the hypothesis that Cdk2 is an Hsp90-dependent 
kinase, we treated K562 myeloid leukemia cells with geldanamycin or DMSO (the drug 
vehicle control) for 0, 12, 24, and 48 hours.  At the indicated times, cells were harvested, 
lysed in sample buffer and then frozen.  Total protein concentration was determined via 
BCA assay, and equal amounts of protein from each cell lysate were analyzed by SDS-
PAGE and western blotting. Little change in Cdk2 levels was observed at 12 hours (Fig. 
16).  However, at 24 hours the level of Cdk2 in geldanamycin treated cells was reduced 
by ~75% (Fig. 16).  These results are consistent with those obtained in studies with other 
Hsp90-dependent protein kinases (118, 168).  
Effects of Hsp90 inhibition on the association of Cyclin A with Cdk2-  Other 
Hsp90 dependent protein kinases become structurally and functionally unstable in the 
presence of geldanamycin (106-108).   Since our results suggested that Cdk2 is a client of 
the Hsp90/Cdc37 chaperone complex, we hypothesized that inhibition of Hsp90’s 
activity with geldanamycin would affect Cdk2’s ability to associate with Cyclin A.  This  
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Fig. 16.  Endogenous Cdk2 protein expression is reduced in geldanamycin treated 
K562 cells. K562 cells were grown in the presence of either DMSO or 0.1 μM GA for 0, 
12, 24, or 48 hours.  Samples were washed, lysed and quantitated by BCA assay. Lysates 
were then ran on SDS-PAGE and western blotted for Cdk2. 
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Fig. 17.  Cdk2 association with Cyclin A in the presence and absence of 
geldanamycin. His-tagged Cdk2 and Cyclin A-AU5 were synthesized in the presence of 
either DMSO or 10 μg/ml GA for 30 min at 30 0C.  Samples were mixed accordingly, 
and immunoabsorbed with the appropriate immunoresin.  All samples were washed with 
P50T once, P500T twice, and P50T once more.  Samples were then separated by SDS-
PAGE and analyzed by autoradiography and western blotted for endogenous Hsp90 and 
Cdc37. 
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was also suggested by the work of Gerber et al which showed that Cdc37 defective yeast 
are unable to properly assemble Cdc28/Cln2 complexes (100), the equivalent of the 
Cdk2/Cyclin  complex. We therefore predicted that the inability of Hsp90 to actively fold 
Cdk2 would prevent Cdk2 from attaining a stable conformation that could be recognized 
by Cyclin A.  To test this hypothesis, we synthesized [35S]-labeled His-tagged Cdk2 and 
Cyclin A-AU5 in separate TnT reactions in the presence or absence of geldanamycin.   
The reaction mixtures were then combined and incubated, and complexes 
immunoadsorbed accordingly.  Samples were then analyzed by SDS-PAGE, 
autoradiography and western blotting for co-adsorption of endogenous Hsp90 and Cdc37 
(Fig. 17). 
 Contrary to our prediction, the autoradiogram indicated that inhibition of Hsp90 
function with geldanamycin had no significant effect on the stoichiometry of the 
interaction between Cyclin A with Cdk2.  Band intensities indicated that when Cdk2 was 
immunoprecipitated Cyclin A co-adsorbed at a constant ratio in the presence or absence 
of geldanamycin. The reciprocal immunoprecipitation of Cyclin A indicated the same.  
Thus, currently in our hands the inhibition of Hsp90 with GA does not seem to have an 
effect on preventing Cdk2 from complexing with Cyclin A. This observation is consistent 
with previous findings in which it was shown that Cdc37 was unable to act as an 
assembly factor for Cdc28/Cln2 complexes (169). Nevertheless, the question of whether 
molecular chaperones play a role in cyclin and cyclin-dependent kinase associations 
deserves more rigorous attention.  
Hsp90 and Cdc37 interactions with C-terminal domain deletion constructs of 
Cdk2-  In our previous work, we observed that Hsp90 was able to interact with deletion 
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constructs of Lck that contained the last two strands of β−sheet (e.g., the β4/5-strands) in 
the N-terminal lobe and the entire C-terminal lobe of the catalytic domain of the kinase.  
In contrast Cdc37 was only found to stably interact with Lck deletion constructs that 
contained the N-terminal lobe αC-helix plus its β4/5-strands, in conjunction with the C-
terminal kinase lobe (163).  These findings were at variance to results from a study 
utilizing Cdk4 in which the G-box was found to be a critical motif required for Cdc37 
binding (141).  Therefore, we decided to use this same approach to define motifs required 
to trigger high-affinity binding interactions between Hsp90, Cdc37 and Cdk2. 
Utilizing the crystal structure of Cdk2 (129), a series of C-terminal lobe deletion 
constructs of His-tagged Cdk2 were prepared (Fig. 18A).  (This data is summarized in 
Fig. 19 and depicted in Fig. 20.) Each of these constructs was expressed by TnT in 
reticulocyte lysate, and samples were immunoadsorbed with anti-His-tag antibody in the 
presence or absence of molybdate.  Samples were then analyzed via SDS-PAGE, western 
blotting, and autoradiography.  Hsp90 and Cdc37 were co-adsorbed with the full length 
His-tagged Cdk2, which was used as a reference and positive control (Fig. 18A).  Based 
on western blot intensities, the amount of the Hsp90 that was co-adsorbed with either the 
NL-β7 construct [which contains conserved kinase motifs I (the G-box) through VIB (the 
equivalent of β−sheets 6 and 7 of PKA (123)] or the NL-Cata construct [which contains 
motifs I through VI (the loop containing the catalytic Asn residue)] was approximately 
one quarter of that which was co-adsorbed with full length Cdk2 in the absence of 
molybdate.  However, in the presence of molybdate, the amount of Hsp90 that co-
adsorbed with the NL-β7 and the NL-Cata constructs was approximately 50% of the 
quantity of Hsp90 that co-adsorbed with the full-length protein.  Furthermore, only 
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marginally detectable levels of Cdc37 were observed to co-adsorb with the NL-β7 and 
NL-Cata constructs, whether or not molybdate was present during the immunoabsorption.  
It is noteworthy that the amount of Hsp90 and Cdc37 that co-adsorbed with the NL-β7 
and the NL-Cata Cdk2 constructs was far less than what was expected.  Based on similar 
experiments carried out with deletion constructs of Lck and Cdk4 (141, 163), we 
predicted that these construct would bind Hsp90 and Cdc37 at 50-75% of the level bound 
by full length Cdk2 in the absence of molybdate, and at a level nearly equivalent to full 
length Cdk2 in the presence of molybdate. 
 The interaction of Hsp90 and Cdc37 with two other Cdk2 C-terminal domain 
deletion mutants [the NL-αE construct, which contains the αE-helix of the CL, but not 
the helix capping motif; and the NL construct which lacks the entire CL and terminates 
after β-sheet 5] was also different than expected from our previous results.  In the 
absence of molybdate, no Hsp90 or Cdc37 that was detectable by western blotting, co-
absorbed with these constructs (Fig. 18A).  In the presence of molybdate, Hsp90 co-
absorbed with the constructs and was detected by western blotting, whereas no co-
adsorbing Cdc37 was detected (Fig. 18A).  Based on our previous results (163), the NL 
and NL-αE constructs were predicted to interact weakly with Hsp90 in the absence of 
molybdate, and molybdate was predicted to stabilize the interaction of both Hsp90 and 
Cdc37 with the Cdk2 NL-αE construct.  
While some of the result described above were somewhat different than expected, 
the data indicated that Hsp90, and to a much lesser extent Cdc37, was only able to bind 
Cdk2 constructs that contain N-terminal kinase lobe and C-lobe motifs through the αE-
helix, complete with its capping motif.  These results support our previous findings with 
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Lck (163), and again emphasize the importance of the stability of the αE-helix, and most 
likely its interface with the hinge-loop motif between the αC-helix and β4-strand in the 
N-terminal kinase lobe.  However, in the presence of molybdate, Hsp90 was observed to 
bind the NL-αE and NL Cdk2 constructs that were void of stably bound Cdc37.  This 
finding differs distinctly from previous work on Cdk4 (141), and our work with Lck 
(163), which demonstrated that Cdc37 was able to bind kinase constructs that contained a 
complete N-terminal lobe, especially after the addition of molybdate (108, 170). 
Hsp90 and Cdc37 interactions with N-terminal domain deletion constructs of 
Cdk2-  To similarly define the high affinity binding interactions of Hsp90 and Cdc37 
with the N-terminal lobe of Cdk2, we prepared a series of N-terminal deletion constructs 
and tested them accordingly (Fig. 18B).  (This data is summarized in Fig. 19 and depicted 
in Fig. 20.)  Hsp90 was co-adsorbed, albeit at a very low level with theβ3-CL [which is 
missing kinase motif I (the G-box)], and marginally with the αC-CL [which starts at 
conserved motif III (the αC-helix which contains an invariant catalytic Glu residue)] 
Cdk2 constructs, with slight increases when molybdate was present to stabilize binding.  
Conversely, the β4-CL construct [which initiates after the hinge-loop in kinase motif IV] 
did not bring down any Hsp90, even in the presence of molybdate.  These results are 
rather consistent with those obtained with N-terminal deletion constructs of Lck, in which 
the interaction of Hsp90 with N-terminal deletion constructs was lost upon deletion of the 
αC-helix (163).  However, the interaction of Hsp90 with the β4-CL construct of Lck was 
stabilized, although at a low level, upon molybdate  
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Fig. 18.  Interactions of Hsp90 and Cdc37 with His-tagged Cdk2 deletion constructs.  
Using a no DNA template as a control for non-specific binding, His-tagged Cdk2 
constructs were synthesized and labeled with 35S-Met in reticulocyte lysate for 30 min at 
30 0C, followed by immunoabsorption with anti-H5 coupled immunoresin in the presence 
or absence of 17 mM molybdate.  All samples were washed with P50T once, P500T 
twice, and P50T once more, no molybdate was present in the wash buffers.  Next, 
samples were separated on an 8% SDS-PAGE gel and western blotted for endogenous 
Hsp90 and Cdc37. Input controls were separated on an 10% SDS-PAGE gel and analyzed 
by autoradiography.  (A) His-tagged Cdk2 C-terminal deletion constructs. (B) His-tagged 
Cdk2 N-terminal deletion constructs. Each deletion construct and its interactions with 
Hsp90 and Cdc37 are further described in Fig. 19. 
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Fig. 19.  Summary of the His-tagged Cdk2 deletion constructs used for the analysis 
of Hsp90 and Cdc37 interactions.  (A) The figure on the left shows the placement of the 
NL and CL of Cdk2 above the conserved structural motifs designated by the Roman 
numerals (as proposed by Hanks and Hunter (123)). The numbers flanking each line 
indicate the first and last residues, respectively in that construct.  (B) The chart on the 
right is aligned with the constructs to indicate the degree of Hsp90 and Cdc37 binding in 
the absence and presence of molybdate: +++, 100% of full length Cdk2; ++, less than 
50% of full length; +, less than 25% of full length; +/-, marginal detection, less than 5% 
of full length; and -, no detectable binding.   
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Fig. 20.  Depiction of the Cdk2 deletion mutant constructs. A different color is shown 
for each segment of Cdk2 deleted in respect to Fig. 19: residues 1-19, red; residues 20-
37, yellow; residues 38-63, cyan; residues 64-82, magenta; residues 83-120, blue; 
residues 121-132, green; residues 133-143, orange; residues144-298, violet.  The kinase 
domain is shown with its ATP binding cleft facing either (A) toward or (B) away from 
the viewer (129). 
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addition, no doubt underlying the significance of the αC-helix and the hinge-loop motif.   
Contrary to results obtained with N-terminal deletion mutants of Lck (163), no 
Cdc37 was detected co-absorbing with any of the N-terminal deletion constructs of Cdk2, 
even in the presence of molybdate.  This result, however, was consistent with results 
obtained with Cdk4 (141), where the G-box was identified as a critical motif for Cdc37 
binding.  In contrast, Hsp90 and Cdc37 do co-absorb with the β3-CL construct of Lck 
(163), even in the absence of molybdate. 
 
Discussion 
 Cdk2 is a cyclin-dependent kinase and a close relative of Cdk4, a well 
documented client of the Hsp90/Cdc37 chaperone complex (125).  Moreover, previous 
studies have shown that Cdc37 associates with and is required for the proper function of 
Cdc28, the yeast homolog of Cdk2 (100, 126, 169).  However, in other studies, a physical 
interaction of Hsp90 and Cdk2 has not been observed (125).  Here we demonstrate that 
Cdk2 indeed physically interacts with both Hsp90 and Cdc37 and demonstrates classic 
client behavior upon inhibition of Hsp90 by GA. 
The reduced rate at which Cdk2 turns over in K562 cells in the presence of GA 
indicates that Cdk2 may not require Hsp90 for maintenance of the stability of mature 
Cdk2 molecules.  The kinetics Cdk2 turnover was much slower than that observed for 
ErbB2 (171), Raf (172) and oncogenic mutants of Lck and Hck (146, 173), which turn 
over at a much higher rate upon treatment with geldanamycin.  Hsp90 is required both for 
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the proper folding of these kinases when they are newly synthesized, and for maintaining 
the stability of the kinases after they have matured to an active form. 
However, our result is consistent with studies on the Hsp90-dependence of other 
protein kinases.  The turnover of wild type Lck (118, 173), Hck (146) and Fyn (168) in 
cells is slow because mature kinase molecules do not depend upon Hsp90 for their 
stability.  Geldanamycin-induced turnover of the kinases is primarily due to the inability 
of cells to replace mature kinase molecules, as they turn over at their normal rate, with 
newly synthesized kinase molecules, which are Hsp90-dependent and very labile in the 
presence of geldanamycin.  Thus, the absence of a requirement for Hsp90 and Cdc37 to 
maintain the stability of mature Cdk2 molecules may explain why it is difficult to co-
absorb Hsp90 and Cdc37 with Cdk2 from cultured cell lysates (data not shown).   The 
Hsp90/Cdc37 dependent population of Cdk2 molecules would be limited to a small 
population of newly synthesized Cdk2 molecules, with the vast majority of Cdk2 in 
cultured cells being mature and stable.  In contrast, the majority of Cdk2 molecules in 
TnT reticulocyte lysate are newly synthesized nascent polypeptides.   
 The results reported here also reaffirm the importance of the αC-helix in protein 
kinases for their proper recognition by and interaction with Hsp90 and Cdc37.  The sc-53 
anti-PSTAIRE antibody, which is directed against residues in the αC-helix of Cdk2, 
blocked the interaction of Hsp90 and Cdc37 with Cdk2.   This observation explains 
results from earlier studies utilizing this antibody, which concluded that Cdk2 did not 
physically associate with Hsp90 and Cdc37 (125).  This finding supports previous work 
with Lck and Cdk4, which indicated that the presence of the αC-helix was required for 
the interaction of Cdc37 with kinase molecules (141, 163).  However, it can not yet be 
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concluded that the αC-helix is the site at which Cdc37 recognizes and binds kinase, as 
the binding of the antibody could block the interaction of Cdc37 by: (i) sterically 
inhibiting the interaction of Cdk2 with Cdc37; (ii) distorting the αC-helix, as antibodies 
are known to bind peptide epitopes in an extended conformation, (iii) altering the 
structure of other regions of the kinase that are dependent on the helix for folding or 
maintaining their structure; or (iv) a combination of these effects. 
Currently, we favor the notion that the binding of the sc-53 antibody to the αC-
helix globally distorts the N- teminal lobe and subsequently reduces the ability of Cdc37 
to interact.  This hypothesis predicts that the αC-helix is required to maintain a number of 
intra-molecular interactions that stabilize the protein and that distortion of the Cdk2 N-
lobe by any number of mechanisms could lead to the loss of Hsp90 and Cdc37 
interaction.  We favor this notion, as it helps to explain the variant results obtain in 
studies on the Lck and Cdk4 kinases (141, 163). 
 While results from the deletion analysis of Cdk2 conflicted with some aspects of 
previous findings carried out on Cdk4 and Lck (141, 163), the primary points of each of 
these studies were upheld. The importance of the G-box in the Cdk4 study, as well as the 
stabilization of the αE-helix reported in the Lck study, were both shown to be critical for 
interaction of Hsp90 and Cdc37 with Cdk2.  Nevertheless, the difference in the 
interaction of Cdc37 with C-terminal deletion mutants of Cdk4 and Cdk2 suggests that 
there are subtle structural differences between the protein kinases.  Sequence alignment 
of the N-terminus of the two catalytic kinase lobes shows that Cdk4 contains an 
elongated αC-helix and extra amino acids within the β3-αC loop and the β4-β5 loop.  
The amino acid residues within these expanded sequences may provide a larger interface 
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for Cdc37 recognition and binding and/or added stability to the interaction of Cdc37 with 
Cdk4.  On the other hand, the β3-αC loop of Cdk4 which is composed of seven 
continuous glycines may instead provide the increased flexibility that allows the N-
teminal lobe to adopt the conformation that can stably interact with Cdc37. 
Interestingly, the importance of the G-box for the interaction of both Cdk4 and 
Cdk2 with Cdc37 may also be related by the fact that the kinase activity of each protein 
can be inhibited by the phosphorylation of residues within this motif (174).  This 
inhibition of kinase activity is most likely due to the distortion of the G-box conformation 
and may signify that slight perturbations of this motif could again have global effects 
upon the overall structure of the NL.  What's more, it should be noted that the G-box of 
the client kinase c-Raf, which much like Cdk4, is critical for Cdc37 interaction (141) may 
also contain a possible regulatory phosphorylation site at S357 or S359.  Furthermore, 
mutation of the third G residue in the G-box of B-Raf to Ala leads to the hyperactivation 
of its kinase activity, an observation that further supports the notion that slight changes in 
the conformation of this region can have significant effects on the structure of the NL 
(175).  
The data presented here further support our previous findings that the stability of 
the interaction of Hsp90 with the catalytic domain of protein kinases requires structural 
motifs present in both lobes of the catalytic domain.  As observed previously for Lck 
(163), stabilization of the C-terminal lobe’s αE-helix, by extending the sequence to 
provide a proper capping motif, seems to be critical for maintaining Hsp90 and possibly 
Cdc37 interaction with Cdk2.   The deletion construct containing a capped αE-helix is 
more likely to retain its α−helical structure and possibly the orientation of its side chains.  
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We postulate that this stabilized α-helix is then able to give the αC-β4 hinge-loop a 
complementary surface interface with which to interact, allowing in turn the semi-stable 
kinase construct to attain a conformation that is recognized by Hp90 and Cdc37.  The 
Cdk4 C-terminal deletion studies also showed that the αC-β4 hinge-loop is required for 
Cdc37 binding, although interestingly enough, further stabilization of the hinge-loop 
structure by the structural motifs following it was not required (141).  It is possible that 
this result is a consequence of expressing the Cdk4 N-terninal lobe as a C-terminal fusion 
to glutathione-S-transferase, in contrast to the expression of the isolated N-terminal lobe 
of Cdk2 described here.   
Probably the most telling evidence supporting the significance of the hinge-loop 
structure is the work of Xu and co-workers comparing the ErbB1 and ErbB2 receptor 
tyrosine kinases (176). ErbB2 was demonstrated to require ongoing interactions with 
Hsp90 and Cdc37 to maintain its cellular stability, whereas ErbB1 required Hsp90 and 
Cdc37 only for its initial folding.   The differences in the stability of each kinase were 
localized to residues in the hinge-loop region.  However, our results support the notion 
that other structural motifs are also likely to be important for Hsp90 binding, such as the 
linker region, which interacts with the hinge-loop region and connects the two kinase 
lobes.  Thus, it appears that while protein kinases share common structural features that 
are recognized by Hsp90 and Cdc37, it is now apparent that there are subtle differences in 
how a client kinase interacts with the Hsp90 chaperone complex, just as how there are 
differences in how kinase activities are regulated through alterations in the interactions 
between the two lobes of their catalytic domains.   
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CHAPTER IV 
Induced Interactions of Hsp90 and Cdc37 with JNK1α1  
 
Introduction 
 Hsp90 is a molecular chaperone that is essential for the biogenesis and 
maintenance of various signal transduction proteins that control all facets of eukaryotic 
cell physiology.  Protein kinases, the largest and most intensely studied family of signal 
transduction proteins, often depend on Hsp90 for their cellular and functional stability.  
The human genome contains 518 genes (120) that encode protein kinases that when 
expressed form multiple cascading networks capable of exponentially amplifying a single 
signal. 
Due to their diverse roles in controlling such processes as cell division, 
differentiation, and apoptosis these protein kinase signaling pathways must be regulated 
by opposing signaling pathways which in turn, create an intricate system of checks and 
balances, pitting one signaling pathway against several others in order to determine the 
fate of the cell.  While it is understood that not all protein kinases are dependent on 
Hsp90, typically at least one member of a signaling pathway or of an opposing signaling 
pathway is an Hsp90 client, thus suggesting Hsp90 also plays a major role in indirectly 
regulating numerous signal transduction events.  
 Hsp90 and its “kinase specific co-chaperone” Cdc37 physically interact with 
protein kinases to support the proper folding and/or stabilization of their dynamic 
structure (reviewed in (96, 97).  While this interaction has been proposed to be initiated 
by Cdc37 recruitment of the kinase client to the Hsp90 chaperone machine (106, 108, 
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111, 125, 144, 145), interaction of Hsp90 with client kinases has been observed in the 
absence of bound Cdc37 (177).  Nonetheless, client kinases are thought to be processed 
by Hsp90 and Cdc37 by a mechanism that is dependent on Hsp90’s nucleotide-mediated 
conformational switching (106-108, 110, 163). 
 Specific structural motifs within the bi-lobal structure of protein kinases are 
required for productive Hsp90 and Cdc37 chaperone interaction (108, 141, 163).   While 
these motifs are located primarily in the N-terminal lobe (NL) of the kinase’s catalytic 
domain, motifs present in the C-terminal lobe (CL) also contribute to the interaction of 
Hsp90 and Cdc37 with kinase domains.  However, the exact manner by which kinase 
motifs are recognized by Hsp90 and Cdc37, and how the Hsp90/Cdc37 interactions with 
these motifs help facilitate the folding of the kinase is not known.  Also not understood is 
why are some protein kinases clients of Hsp90 and Cdc37 while others are not, and which 
chaperone is responsible for this selection, Hsp90 or Cdc37? 
 Mitogen and stress activated protein kinase (MAPK/SAPK) pathways are 
conserved networks of protein kinases arranged in multiple tiers capable of transducing 
numerous signals.  At the distal ends of the signaling pathway are the MAPK/SAPK 
themselves, p38, ERK, and JNK, which phosphorylate specific sets of proteins, most 
often transcription factors which result in altered gene expression.  Initiating and/or 
transducing the signaling cascade are the upstream kinases, MAPK kinases (MAPKK) 
and MAPKK kinases (MAPKKK), which phosphorylate and activate the downstream 
effector MAPK/SAPKs (130, 178). 
Most MAPK/SAPKs are comparatively similar in structure and function and have 
not been shown to be Hsp90 or Cdc37 clients.  However, many of the upstream kinases 
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(MAPKKs and MAPKKKs) that activate MAP kinases are Hsp90 clients (179-182).  The 
structures of the majority of MAPK/SAPKs are relatively simple when compared to the 
upstream MAPKKs and MAPKKKs Hsp90 client kinases, which contain one or more 
additional regulatory domains responsible for the binding of specific effectors.  While 
many MAPK/SAPKs contain additional motifs either upstream or downstream of their 
catalytic core (131, 183, 184), these kinases lack major regulatory domains, and as a 
result, the activation of MAPK/SAPKs is usually stimulated simply by the 
phosphorylation of specific sites in their activation loop (185).   
However, most MAPK/SAPKs possess two non-catalytic structural motifs 
(NCSMs) flanking the kinase domain that are currently not found in Hsp90 client kinases.  
The N-terminal non-catalytic structural motif (NSM) is two anti-parallel β-sheets 
preceding motif I (G-box) which lie on top of the other β-sheets of the NL and form a β-
sandwich.  The C-terminal non-catalytic structural motif (CSM) is a large extended 
region that is not completely defined in MAPK/SAPK crystal structures. Although the 
regions that are defined indicate that the CSM wraps around the kinase domain 
interacting with both the alpha-E helix in the CL and αC-helix in the NL.  These 
MAPK/SAPK structural motifs have been shown to be important in stabilizing kinase 
activity and in the cellular localization of the kinase, as well as the binding of substrates, 
upstream kinases, scaffold proteins and phosphatases (186-189).  However, whether these 
motifs provide MAPK/SAPKs with the added structural stability that allows them to 
function independent of Hsp90 and Cdc37 has not been determined.   
In this report, we have used deletion mutagenesis and the classic Hsp90 inhibitors, 
geldanamycin (GA) and molybdate, to examine the role that the N- and C-terminal 
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flanking motifs play in mediating Hsp90 and Cdc37 interactions with the SAPK, 
JNK1α1.  Consistent with our previous findings, we show that Hsp90 and Cdc37 
recognize structural features found within the N-terminal lobe of the protein kinase, while 
Hsp90 also recognizes other features within the C-terminal lobe (108, 163).  
Additionally, our results suggest a novel mechanism by which Cdc37 recognizes kinases 
and possibly recruits them to Hsp90.  Consequently, these results increase our 
understanding of why some protein kinases interact with Hsp90 and Cdc37, and some 
apparently do not. 
 
Experimental Procedures 
Plasmids. The original pcDNA 3.1-Flag-JNK1α1 plasmid was a gift from Dr. Roger 
Davis. All plasmids coded for an N-terminal Flag-tagged JNK construct under a T7 
promoter.  The N-terminal truncation construct, JNKΔNt (residues 28-384), was made by 
amplifying the original pcDNA 3.1-Flag-JNK1α1 by PCR, but using a 5’ primer that 
deleted the first 27 residues.  The 5’ primer also contained 15 bases on its 5’ end that 
were the same as another primer that encoded the Flag-tag.  The first PCR product was 
amplified again using this Flag-tag primer and then ligated into pcDNA3.1-Topo 
(Invitrogen) according the manufactures specifications.  The C-terminal truncation 
constructs, JNKΔCt (residues 1-322) and JNKΔNtCt (residues 28-322), were made by 
mutating the 323 codon into a stop codon via QuickChange (Stratagene). Mutation of the 
activation loop residues T183 and Y185 (TPY) to Ala and Phe (APF) or Glu (EPE) was 
also done using QuickChange. 
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Co-immunoprecipitations of chaperones with Flag-tagged JNK1α1 deletion constructs. 
Using a no DNA blank as a control for non-specific binding (NS), each construct was 
synthesized and radiolabeled with [35S]-Met by coupled transcription/translation in 25-35 
μl T7 Quick Master Mix (Promega) for 30 minutes at 300 C.  In indicated experiments 
synthesis was done in the presence of either DMSO or 10 μg/ml GA, and in some 
experiments 20 mM molybdate was added after synthesis was completed.  All 
immunoprecipitation samples were immediately placed on ice, clarified by centrifugation 
by a Fisher 235c microfuge at 40C for 5 min and immunoabsorbed with 25-30 μl of anti-
mouse immunoresin coupled to mouse anti-Flag (Sigma) antibody.   Immunoresins were 
then washed once with P50T (10 mM Pipes (pH 7.2), 50 mM NaCl, and 0.5% Tween-
20), two times with P500T (same as P50T except with 500 mM NaCl), and again with 
P50T.  No molybdate was present in the wash buffers.  Finally, the samples were boiled 
in SDS sample buffer, separated on an 8% SDS-PAGE gel, transferred to PVDF 
membrane, analyzed by autoradiography for equal expression and blotted for both 
endogenous Hsp90 and Cdc37 (108). 
 
JNK kinase assay. Immunoresins were washed twice with P500 (no Tween-20) and twice 
with P150.  Samples were then incubated with 30 μl of kinase buffer (25 mM Pipes pH 
7.4, 10 mM MgCl2, 2 mM DTT, 10 mM glycerophosphate, 2.5 mM NaF, and 200 
μΜ ATP) and 0.5 μg of c-Jun (1-89)-GST (Cell Signaling) for 15 minutes at 370C.  
Finally, samples were boiled in SDS sample buffer, separated on an 8% SDS-PAGE gel, 
transferred to PVDF membrane, and blotted with anti-phospho c-Jun (Ser63 ) (Cell 
Signaling Technology).   
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Results 
JNK1α1 deletion constructs interact with Hsp90 and Cdc37.   The c-Jun N-
terminal kinase (JNK) group of kinases is encoded by three genes that produce a total of 
10 splice variants. Each splice variant differs in its substrate binding motif and/or C-
terminal structural motif size (190).  In this work, we have studied the 46 kDa isoform, 
JNK1α1, which contains the smaller of the C-terminal structural motifs. 
While the cellular stbility of numerous protein kinases have been shown to 
depend upon the Hsp90/Cdc37 molecular chaperone complex (14, 15, 96, 97, 135, 191, 
192), the cellular stability of JNK does not seem to be affected by Hsp90 inhibition (181, 
193, 194).  Thus, JNKs appear to be Hsp90-independent kinases.  To understand this 
phenomenon, we attempted to determine what structural motifs within JNKs confer or 
defer Hsp90 and Cdc37 interaction.  Structural alignment and comparisons of the crystal 
structures of MAPK/SAPK members ERK (184), JNK (131) and p38 (183) with Hsp90 
dependent kinases Cdk2 (129), Akt (195), and Lck (196) indicated that the MAPK/SAPK 
member kinases possess additional structural motifs at the immediate ends of both their 
N- and C-terminal lobes of their catalytic domains (alignment not shown).  The N-
terminal motif consists of two additional strands of anti-parallel β−sheet yielding a β-
sandwich like structure.  The extended C-terminal motif of JNK wraps around the NL to 
pack an α-helix against the αC-helix which contains a Glu required for catalysis of 
phosphate transfer. An α-helix present in cyclins similarly interacts with the αC-helix in 
Cdks to stabilize its rotation and direct the side chain of its catalytic Glu into the active 
site (197).   
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Additionally, the position of the activation loop was investigated to determine if it 
played some role in Hsp90 and Cdc37 interaction. This was suggested by the fact that the 
activation loops in the inactive conformation of MAPK/SAPKs lie close to the G-box, a 
motif found to be required for Cdc37 interaction with both Cdk4 and Cdk2 (141).  
However, when the activation loops of MAPK/SAPKs are phosphorylated they move 
away from the G-box and fold down along the CL which results in activation of the 
kinases (185).   
Our previous work indicated that antibody directed against sequences within the 
αC-helix blocked the binding of Cdc37 to Cdk2, leading us to speculate that Cdc37 may 
play a role in stabilizing the rotation of the αC-helix within the NL of protein kinases.  
To test this hypothesis, we prepared a series of wild type N-terminal Flag-tagged deletion 
constructs of JNK1α1: ΔNt (28-384), ΔCt (1-322), and ΔNtCt (28-322).  Furthermore, to 
test whether the position of the activation loop played some role in Hsp90 and Cdc37 
interaction residues T183 and Y185 (TPY) were mutated to either Ala and Phe (APF) or 
both to Glu (EPE), in order, to code for a constitutively inactive or active kinase, 
respectively.  [35S]-labeled full length JNK, deletion constructs and point mutants were 
synthesized by coupled transcription/ translation in reticulocyte lysate, 
immunoprecipitated with anti-Flag agarose resin, and assayed for co-absorption of Hsp90 
and Cdc37 by western blotting (Fig. 21).  As previous work suggested (181, 193, 194), 
Hsp90 and Cdc37 did not co-absorb with full length JNK or any of its point mutants.  
However, Hsp90 co-absorbed with all of the deletion constructs.  In contrast, Cdc37 co-
absorbed with only the ΔNt construct and was only marginally detectable with the ΔNtCt 
construct.   This reduced binding of Cdc37 to ΔNtCt constructs is possibly a result of the 
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added instability afforded by the removal of the CSM. Furthermore, it appears that 
mutating of T183 and Y185 had no significant effect on Hsp90 or Cdc37 interaction (Fig. 
21). 
These observations (Fig. 21) were somewhat contrary to our previous speculation 
that Cdc37 may play a role in stabilizing the rotation of the αC-helix within the NL of 
protein kinases (108, 163). We anticipated that the ΔCt construct would bind Cdc37 and 
Hsp90, while the ΔNt would have little or no interaction with Hsp90 or Cdc37.  Instead, 
co-adsorption of Cdc37 with the ΔNt construct suggests that the NSM prevents Cdc37 
from recognizing the motifs required for its binding.  Thus, the role of Cdc37 may be to 
stabilize the β-sheet structure in the N-terminal lobe rather than the αC-helix.  This 
notion is further supported by the significant reduction in the co-adsorption of Cdc37 
with the ΔNtCt compared to the ΔNt construct, indicating that exposure of the backside 
of the αC-helix does not enhance the binding of Cdc37 to the mutant JNK construct.  
 The association of Cdc37 with all nascent client kinases that have been 
investigated so far has always been accompanied by Hsp90 (108, 145, 163, 170).  
Therefore, the co-absorption of Hsp90 with the ΔNt construct was not unexpected (Fig. 
19).  However, the co-absorption of Hsp90 and not Cdc37 with the ΔCt construct 
suggested that Hsp90 may interact with the ΔNt and ΔCt constructs differently.  Thus, the 
interaction of Hsp90 with the ΔNt construct may be coordinated by Cdc37, while the 
interaction with the ΔCt construct may be due to the unmasking of another putative 
binding site that is recognized by Hsp90 only.  This hypothesis is consistent with our 
previous findings that the interaction of Hsp90 with multiple discrete segments of client 
kinases is required to trigger the high affinity binding of Hsp90 (108, 163).  
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Fig. 21.  Interactions of Hsp90 and Cdc37 with JΝΚ1α1 deletion constructs and 
activation loop point mutants.  Using a no DNA blank as a control for non-specific 
(NS) binding, Flag-tagged JΝΚ1α1 deletion constructs and point mutants were 
synthesized and labeled with 35S-Met in 35 μl of reticulocyte lysate for 30 min at 30 0C, 
followed by immunoabsorption with anti-Flag immunoresin.  All samples were washed 
with P50T once, P500T twice, and P50T once more.  Samples were then run on SDS-
PAGE and western blotted for co-absorbing endogenous Hsp90 and Cdc37, according to 
“Experimental Procedures”.  
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Geldanamycin effects on Hsp90 and Cdc37 interactions with JNK1α1 deletion 
constructs.  To further characterize the interactions of Hsp90 and Cdc37 with the JNK 
deletion constructs, we tested the effects of the Hsp90 inhibitor geldanamycin on both the 
ability of the JNK constructs to bind Hsp90 and Cdc37 and to phosphorylate the N-
terminus of c-Jun (Fig. 22).  Geldanamycin works by binding to the N-terminal ATP 
binding site of Hsp90 (37), which blocks ATP-induced “clamping” of the N-terminal 
domains within dimeric Hs90, and prevents Hsp90 and Cdc37 from forming a high-
affinity salt-resistant heterocomplexes with client kinases (107).  This property of 
geldanamycin allows one to test whether a client kinase interacts with Hsp90 and Cdc37 
in the classical manner by observing whether the chaperones dissociate upon washing 
with buffer containing 0.5M NaCl (107, 108). 
Full length wild type JNK and deletion mutant constructs were synthesized and 
[35S]-labeled in coupled transcription/ translation in reticulocyte lysate, and 
immunoabsorbed with anti-Flag agarose resin. After washing the resins with buffer 
containing high salt, the samples were analyzed for co-absorption of Hsp90 and Cdc37 by 
western blotting (Fig. 22).  Similar to the results described above, in the absence of 
geldanamycin, Hsp90 was co-adsorbed with each of the deletion mutants, while Cdc37 
co-absorbed with the ΔNt construct and marginally with the ΔNtCt construct.  
Interestingly, in the presence of geldanamycin, Hsp90 still co-absorbed with the ΔNt and 
ΔNtCt constructs, although to a much lesser degree than in the absence of geldanamycin.  
However, the amount of Hsp90 that co-adsorbed with ΔCt was significantly reduced in 
the presence of geldanamycin.  In addition, no Cdc37 co-absorbed with any of the 
deletion constructs in the presence of geldanamycin.  Furthermore, no deletion construct 
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was able to phosphorylate the N-terminus (Ser63) of c-Jun after being synthesized in the 
absence or presence of geldanamycin, whereas full length JNK was able to phosphorylate 
the N-terminus of c-Jun after being synthesized under either condition. Thus, the NCSMs 
are required to maintain kinase activity, and the binding of Hsp90 and/ or Cdc37 does not 
correct the functional defects induced upon deletion of these motifs from JNK.  This 
supports previous findings which demonstrated that the NSM is required for kinase 
activity in Erk2 (187). 
 Again, these observations (Fig. 22) did not totally support the predictions of our 
original hypothesis that Hsp90 and Cdc37 would be completely dissociated from the 
mutant kinase constructs in the presence of geldanamycin.  True to previous observations 
(107, 108), Cdc37 did dissociate from all of the constructs in the presence of 
geldanamycin, indicating that Cdc37 can not productively interact with client kinases 
when they are bound to Hsp90 in its geldanamycin-bound conformation.  In addition, the 
notable reduction in the amount of Hsp90 that co-absorbed with the ΔCt construct in the 
presence of geldanamycin suggests that Hsp90 is being arrested in its open “unclamped” 
conformation.  This observation suggests that Hsp90 interacts with the ΔCt construct in a 
manner similar to its previously characterized interactions with natural client kinases 
(108, 135).  Thus, Hsp90 may recognize and interact with specific structural motifs on 
natural client kinases that are masked in MAPK/SAPKs by the CSM. 
However, the finding that Hsp90 in its geldanamycin-bound conformation did not 
completely dissociate from the ΔNt and ΔNtCt constructs suggests that Hsp90 might be 
interacting with these constructs in a novel manner that has not been previously observed.  
This interaction was dependent on the removal of the NSM and not mediated by Cdc37,  
 100
 
 
 
 
 
  
Fig. 22.  Kinase activity and interactions of Hsp90 and Cdc37 with JΝΚ1α1 deletion 
constructs in the absence and presence of geldanamycin.  Using a no DNA blank as a 
control for non-specific (NS) binding, Flag-tagged wild type JΝΚ1α1 deletion constructs 
were synthesized and labeled with 35S-Met in 25 μl of reticulocyte lysate for 30 min at 30 
0C in the presence of either DMSO or 10 μg/ml GA, followed by immunoabsorption with 
anti-Flag immunoresin.  All samples were washed twice with P500 and twice more with 
P150. Kinase buffer and c-Jun (1-89)-GST was then added. Samples were then incubated 
at 37 0C for 15 min and then run on SDS-PAGE and western blotted for phospho c-Jun 
(Ser63) and co-absorbing endogenous Hsp90 and Cdc37, according to “Experimental 
Procedures”. 
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Fig. 23.  Interactions of Hsp90 and Cdc37 with JΝΚ1α1 deletion constructs in the 
absence and presence of molybdate.  Using a no DNA blank as a control for non-
specific (NS) binding, Flag-tagged wild type JΝΚ1α1 deletion constructs were 
synthesized and labeled with 35S-Met in 25 μl of reticulocyte lysate for 30 min at 30 0C 
followed by immunoabsorption with anti-Flag coupled immunoresin in the presence or 
absence of 17 mM molybdate.  All samples were washed with P50T once, P500T twice, 
and P50T once more.  Samples were then run on SDS-PAGE and western blotted for co-
absorbing endogenous Hsp90 and Cdc37, according to “Experimental Procedures”.  
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suggesting that Hsp90 may interact with client kinases through more than one 
mechanism. 
 Molybdate effects on Hsp90 and Cdc37 interaction with JNK1α1 deletion 
constructs.  The addition of molybdate stabilizes interactions of Hsp90 and Cdc37 with 
client proteins by locking Hsp90 in its clamped “slow on/slow off” conformation (107, 
108, 163). This allows Hsp90 and Cdc37 to form highly salt resistant heterocomplexes 
with the client protein. To further characterize the interactions of Hsp90 and Cdc37 with 
the wild type JNK deletion constructs, full length JNK and each deletion construct was 
synthesized by coupled transcription/ translation in reticulocyte lysate, and 
immunoprecipitated with anti-Flag agarose resin in the presence or absence of molybdate. 
The immuno-resins were then washed with buffer containing 0.5 M NaCl, and analyzed 
for co-absorbing Hsp90 and Cdc37 by western blotting (Fig. 23).  In the presence of 
molybdate, the amount of Hsp90 that co-absorbed with each of the deletion constructs 
was equal to or greater than the amount co-adsorbed in the absence of molybdate.  Cdc37 
again co-absorbed with ΔNt with a subtle increase in the amount co-adsorbed in the 
presence of molybdate.  However, the amount of Cdc37 that co-absorbed with ΔNtCt 
remained marginal.  These observations are consistent with the effect of molybdate on the 
interactions of Hsp90 and Cdc37 with natural client kinases (107, 108, 163).  
Surprisingly, in the presence of molybdate, Hsp90 but not Cdc37 co-adsorbed with full 
length JNK. 
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Discussion 
 JNK1α1 is not an Hsp90 or Cdc37 associating client kinase.  However, in this 
report we demonstrate that deletion of the non-catalytic structural motifs present at the N- 
and C-terminus of JNK1α1 can induce the binding of Hsp90 and/or Cdc37 (summarized 
in Fig. 24 and depicted in Fig. 25).  The characteristics of these induced interactions only 
partially resemble those of Hsp90/Cdc37 with natural client kinases, which are weakened 
by geldanamycin while strengthened by molybdate (107, 108, 163).  Furthermore, our 
findings suggest that Hsp90 may interact with protein kinases through two distinct sites.  
This hypothesis is supported by the differences observed between the binding of Hsp90 
to the ΔNt and ΔCt constructs in the absence and presence of geldanamycin.  Previously, 
deletion mutagenesis work with Lck also suggested that Hsp90 recognizes at least two 
distinct sites in kinases, as Hsp90 associates with non-overlapping constructs of both the 
NL and CL of Lck in the presence of molybdate (108, 163).  Thus, these results suggest 
that Hsp90 and Cdc37 may recognize and bind specific structural motifs whose 
accessibility are masked or whose conformations are altered or stabilized by their 
interactions with the NSM and CSM in MAPK/SAPKs, and suggest a rationale for why 
some kinases interact with Hsp90 and Cdc37, and some do not. 
 The Hsp90 interaction site, which is “unmasked” by the deletion of the NSM, is 
recognized by Hsp90 even in the presence of geldanamycin, while the interaction of 
Cdc37 with this site remains sensitive to inhibition by geldanamycin.  Notably, the 
characteristics of interaction of Hsp90 and Cdc37 with the ΔNt construct in the presence 
of GA is similar to their interactions with Akt (177).  Akt appears to remain associated 
with Hsp90 after its maturation and dissociation of Cdc37.  Crystallographic studies 
 104
indicate that the C-terminus and N terminus of the αB and αC-helices in Akt are 
intrinsically unstructured in the absence of the phosphorylation of  S474 (195), which 
facilitates the activation of Akt (198).  The congruence of this data suggests that the 
deletion of the NSM likely prevents the NL of JNK from folding properly, and that the 
stability of Hsp90’s interaction with mis-folded or intrinsically disordered polypeptides is 
not dependent on nucleotide-mediated conformational switching. 
 The characteristics of the interaction of Hsp90 with the ΔCt construct in the 
presence and absence of geldanamycin is typical of the characteristics of its interactions 
with most Hsp90-dependent kinases (108, 135).  This observation suggests that the site 
that is unmasked or whose conformation is altered upon deletion of the CSM contains a 
binding site for Hsp90 that modulates Hsp90’s nucleotide-mediated conformational 
switching.  However, the lack of interaction of Cdc37 with the ΔCt construct indicates 
that simply exposing the face of the αC-helix is not sufficient to induce Cdc37 binding, 
as we had previously speculated (108, 163, 170). 
 The interaction of Cdc37 with the ΔNt and ΔNtCt JNK constructs is consistent 
with previous work that indicated that Cdc37 interacts with motifs present in the NL of 
the catalytic domain of protein kinases (i.e., Lck, HRI, Cdk4, and Cdk2) (108, 141, 170).  
Our current findings further support the notion that the role of Cdc37 in chaperoning 
protein kinase folding is to stabilize the N-terminal lobe of the protein. However, our 
current work suggests that Cdc37 may mimic the role of the NSM β-sheet structure in 
stabilizing the structure of the NL of MAPK/SAPKs, a role distinctly different than our 
previous hypothesis that Cdc37 may interact directly with the αC-helix of kinases to 
stabilize its orientation within the catalytic site (108, 163, 170).  
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Fig. 24. Summary of the Flag-tagged JNK deletion constructs used for the analysis 
of Hsp90 and Cdc37 interactions. (A) The figure on the left depicts the location of 
NSM, NL, CL and CSM of JNK1α1. The numbers flanking each line indicate the first 
and last residues, respectively of that construct.  (B) The chart on the right is aligned with 
the constructs to indicate the degree of Hsp90 and Cdc37 binding in the absence and 
presence of GA and molybdate: ++, 100-90% of maximum binding; +, 50% of maximum 
binding; +/-, marginally detectable, less than 10% of maximum binding; -, no detectable 
binding.   
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Fig. 25. Depiction of the non-catalytic structural motifs studied. Using the JNK3 
crystal structure (131) (PDB: 1JNK) as a model the following structural features are 
depicted: NSM, yellow; NL, blue; linker, magenta; CL, green; CSM, red. ATP binding 
cleft is shown facing (A) toward, and (B) away from the viewer. 
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Our current findings suggest that Cdc37 may interact with client kinases to 
stabilize and/or nucleate the folding of the single-layered β−sheet structure present in the 
NL of Hsp90-dependent kinases.  Single layers of β-sheets are not present in proteins, as 
they are unstable due to the exposure of the hydrophobic face of the sheet to water.  Thus, 
the structure of the NL of kinases may require the interaction of its single layered β-sheet 
structure with Hsp90/Cdc37 to stabilize the NL until the synthesis of the kinase is 
complete, or the structure of kinase is adjusted to align or stabilize the interface between 
the two lobes.  Regulation of the activity of protein kinases characteristically involves 
reorientation of the interface between the N- and C-lobes to properly align the amino acid 
residues that catalyze the phosphotransferase reaction (162, 185, 199).   
Furthermore, at the interface between the NL and CL of protein kinases, the 
hydrophobic face of the NL provides the surface that interacts with the adenine ring of 
ATP.  In the absence of bound nucleotide, the NL of protein kinases may be prone to 
denaturation, because of the exposure of the nucleotide-binding cavity to water.  The 
notion that protein kinases may be unstable during the process of nucleotide exchange is 
supported by the observation that binding of the Src-family kinase inhibitor PP2 to a 
constitutively activated mutant of Lck, which requires Hsp90 and Cdc37 to maintain its 
function even after its initial maturation, stabilizes the protein in the presence of 
geldanamycin (200).   
Cdc37 likely provides the major activity that stabilizes and/or facilitates the 
structure and/or folding of the NL of kinases.  This hypothesis is supported by the 
observations that: (i) Cdc37 appears to interact exclusively with components of the NL of 
kinases; (ii) a deletion mutant of Cdc37 that does not bind Hsp90, binds kinase, and acts 
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as a dominant-negative inhibitor of kinase folding (106, 145); and (iii) the JNK ΔCt 
construct bound Hsp90, but not Cdc37.  While Cdc37 may function to mimic the β-sheets 
of the NSM, it is also possible that deletion of the NSM simply allows the NL to adopt an 
altered conformation that is recognized by Cdc37.  Thus, the NSM may not prevent 
Cdc37 interaction by simply physically blocking the binding site, but the NSM may 
stabilize the kinase structure so that it cannot be recognize by Cdc37.  Furthermore, 
Cdc37 might possibly interact with the underside of the single layered β-sheet masking 
the hydrophobic residues that form the nucleotide binding cavity from the aqueous 
environment, prior to its packing against the CL.   
 While our current work suggests that the topology of the β-sheet structure of the 
NL of kinases is an important determinant for the interaction of a kinase with Cdc37, it 
does not address the disparities observed between the characteristics in Cdc37 binding to 
different protein kinase families.  Deletion mutagenesis work with the Src-family 
member Lck showed that the first three strands of β-sheets within the NL were not 
needed for Cdc37 binding suggesting that the αC-helix and the fourth and fifth strands of 
β-sheets were the required structure for Cdc37 recognition (163), while work done with 
Cdk4 has indicated that the first three strands of β−sheet, the αC-helix and residues in the 
loop connecting the αC-helix to the β4-strand were required for Cdc37 binding (141).  
However, our work with Cdk2 essentially showed that nearly the complete NL was 
needed for Cdc37 binding.  Taken together these observations suggest that subtle 
differences between the structures of the NL of kinases structure may equate to profound 
differences in the recognition and binding of Cdc37 to the kinase, which ultimately may 
only be understood through X-ray crystallography and NMR studies. 
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CHAPTER V 
Discussion 
Summary 
 The work presented in this thesis focuses the interactions between protein kinases 
and the molecular chaperones Hsp90 and Cdc37.  Three different protein kinases from 
three different phylogenetic families were studied using deletion mutagenesis, in order to 
determine the structural motifs recognized and bound by Hsp90 and Cdc37.  Each study 
utilized classic co-immunoadsorption in the presence or absence of the Hsp90 inhibitors 
GA and molybdate to verify Hsp90 and Cdc37 association.  Although each study yielded 
different results, certain interactions remained consistent.  These interactions being: (i) 
Cdc37 recognizes and binds primarily to the NL of protein kinases; (ii) this interaction is 
accompanied by Hsp90; and (iii) Hsp90 also recognizes certain structural features in the 
CL, that when present along with NL allow for nucleotide-mediated conformational 
switching of the chaperone complex. 
 The use of deletion mutagenesis to define the structural motifs required for Hsp90 
and Cdc37 association is an effective technique for defining the broad strokes of the 
interaction.  However, since these interactions do not seem to be based on amino acid 
sequence or a defined structure within the kinas,e using this technique creates a slippery 
slope when trying to determine the finer points of these interactions.  This ambiguity is 
exemplified by the differences in Hsp90 and Cdc37 binding between the three different 
kinases.  It is also illustrated by data that was not shown on the numerous Lck catalytic 
subunit construct (CAT) point mutants designed to disrupt chaperone interaction that 
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bound Hsp90 and Cdc37 with the same affinity as wild type, thus providing no 
information on what specific residues and motifs are critical for recognition and binding 
of Hsp90 and Cdc37 to protein kinases.  Therefore, although this work yielded some 
critical information on the interactions of Hsp90 and Cdc37 with protein kinases, in the 
end it became akin to trying to split a hair with a sledgehammer.  In retrospect, this is a 
likely outcome when using structural disrupting techniques to study a complex whose 
role is to bind and secure structurally unstable clients. 
 However, further work is needed to extend upon the findings in this report and 
explain some of the apparent discrepancies relative to kinase motifs recognized by Hsp90 
and Cdc37.  The study of a broader range of kinases from both Hsp90 dependent and 
independent families could provide more clues relative to what Hsp90 and Cdc37 
recognize and bind.  This should include kinases that function and/or exist as monomers 
or dimers and are either activated by hetero-phosphorylation or trans-
autophosphorylation.  Point mutagenesis of Cdk2 may also give some ideas of the 
specific residues and motifs needed for Hsp90 and Cdc37 binding.  This approach may be 
productive with Cdk2 because its interaction with the chaperone heterocomplex does not 
seem to be as robust as Lck and may be easily disrupted by subtle sequence perturbations, 
as seen in the work with its relative Cdk4 (141).  A finer dissection of the NCSMs of 
JNK1α1 is another approach that may yield more clues to what structural motifs are 
recognized and bound by Hsp90 and Cdc37, yet masked in MAPK/SAPKs.  In the end 
though, the use of NMR and X-ray crystallography will be required to truly understand 
the interactions of protein kinases with Hsp90 and Cdc37. 
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Cdc37 Interactions  
 The role of Cdc37 is to recognize and bind specific structural motifs within the 
NL of protein kinases (141, 163). The KBD of Cdc37 is the most conserved domain 
across all species.  Although its structure is unknown, the structural prediction program 
PONDR (201) suggests that most of the KBD is relatively unstructured.  Initial NMR 
studies appear to confirm this prediction.  It seems plausible that the unstructured nature 
of the KBD may be needed to adopt subtle variations in conformation, in order to bind 
the NL of different protein kinases.    On the other hand, secondary structure prediction 
programs suggest that the first 40 residues of Cdc37, which are the most conserved 
phylogenetically, adopt a random coil or β−sheet structure that is followed by a coiled-
coil motif, although the work with JNK1α1 currently suggests that the KBD structure 
somehow replaces a set of anti-parallel β-sheets that stabilizes the structure of the NL in 
native JNK.  
 Cdc37 is possibly the first chaperone to recognize and bind nascent protein kinase 
polypeptides as they emerge from the ribosome.  The observation that Hsp90 and Cdc37 
interact with nascent HRI polypeptides co-translationally first insinuated this possibility 
(106).  Yet, the fact that Cdc37 only binds to the NL of kinases (108, 163), which often 
times is the first available domain for chaperone interaction, suggests that Cdc37, along 
with possibly the Hsp70 network, is the first chaperone to initiate the folding cycle of 
nascent kinases.  The loss of Cdc37 association with the N-terminal deletion constructs of 
Lck and Cdk2 also support the notion that Cdc37 initiates proper kinase folding (141, 
163).  However, the fact that Hsp90 can still bind these N-terminal deletion constructs in 
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the presence of molybdate, suggests Hsp90 possibly binds after Cdc37 and at a different 
site (108, 163).  These observations taken together suggest that proper binding and 
folding of wild type kinases may be accompanied by nucleotide mediated conformational 
switching of the chaperone complex independent of molybdate, and that Cdc37 may need 
to associate with the NL first, which is subsequently followed by the recruitment and 
binding of Hsp90. 
 The possibility that Cdc37 recruits the kinase polypeptide to Hsp90 puts forth a 
model in which Cdc37 acts similar, yet independent of Hop in transferring the kinase 
polypeptide from the Hsp70 network to the Hsp90 chaperone machine.  Local amino acid 
sequence alignment of Cdc37 with Bag-1M and Hop has revealed that Cdc37 possesses a 
short conserved region with sequence similarity to each of these co-chaperones.  The 
local sequence alignment of human Cdc37 and the Hsp70 nucleotide exchange factor, 
Bag-1M shows that Cdc37 possesses most of the highly conserved residues that are 
needed for Bag-1M to directly interact with the ATPase domain of Hsp70 (75).  This 
interaction allows for the exchange of ATP for ADP along with the coordinated release of 
the client polypeptide.  In Cdc37, this Bag-like motif (BLM) is predicted to have a 
coiled-coil structure and is found just outside of the highly conserved first 40 amino acids 
of the KBD [41-67 aa] (Fig. 26A).  Bag has been shown to have a coiled-coil structure, 
and unpublished data of Jieya Shao has shown that Cdc37 does indeed interact with the 
ATPase domain of Hsp70.   
 The other local sequence alignment of human Hop and Cdc37 is found in both 
proteins on the N-terminal side of the Hsp90 binding domains: TPR2a in Hop [210-224 
aa] and HBD in Cdc37 [131-146 aa] (Fig. 26B).  This part of the HBD of Cdc37 has been  
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             206               -----------------------                     238 
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            210        225 
Hop    T K P E P M E E D L P E N K K Q 
           :  :  :   :          :  :  :          :       .   .  : 
Cdc37 T K P E K T E E D S E E V  R E Q 
                                             131                                                 146 
 
Fig. 26.  Local alignment of human Cdc37 with human Bag-1M and Hop.  (A) The 
helical region of Bag-1M that directly interacts with the ATPase domain of Hsp70 aligns 
with a region that lies within the KBD of Cdc37. The residues of Bag-1M that are 
conserved across all species and have shown to be required for Hsp70 interaction are 
shown in bold.  Also, a variable region of Bag-1M and its homologues is indicated.  (For 
further details see Shao, J., 2002 OSU Thesis pg.125) (B) The D2a domain of Cdc37 
aligns with the region of Hop that precedes the Hsp90 binding TPR2a domain.  
 
 
 
 
 
 
 
 
 
A 
B 
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Fig. 27. Cdc37 modified Hsp70/Hsp90 Chaperone Cycle.  (1) As the protein kinase 
emerges from the synthesizing ribosome, Cdc37 binds to the NL of the kinase with its 
KBD while at the same time Hsp40 and Hsp70 recognize and bind the nascent 
polypeptide.  Hsp90 is recruited into this “early complex” also during this time through 
the HBD of Cdc37. (2) Once the supposed “intermediate complex” is assembled, Cdc37 
induces Hsp70 and Hsp40 to dissociate from the complex via Cdc37’s Bag-like motif 
(BLM). While possibly at the same time, Cdc37 causes Hsp90 to bind ATP and tightly 
bind the client kinase. This is followed by the association of the “late complex” co-
chaperones.  (3) Eventually, Hsp90 hydrolyzes the bound ATP to ADP and releases the 
functional kinase. (4) Possibly after sometime, the client kinase becomes unstable. (5) 
Cdc37 recognizes the unstable client kinase and binds it, in the process re-recruiting it 
back into the Hsp70/Hsp90 chaperone cycle. 
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referred to as D2a; and interestingly its deletion from constructs of Cdc37’s Hsp90 
binding domain (D2) causes the construct to bind Hsp90 stronger in the presence of GA 
and weaker in its absence (110).   This observation suggests this motif in Cdc37 and Hop 
may play some role in modulating nucleotide-mediated conformational change, which in 
turn modulates client binding.  
 A speculative model for Cdc37’s participation in Hsp90’s chaperone cycle could 
be described accordingly (Fig. 27).  Cdc37 recognizes and binds the NL of the nascent 
kinase polypeptide as it emerges from the ribosome.  This possibly occurs along with 
Hsp40 and Hsp70 binding to the polypeptide.  Hsp90 is recruited via the HBD of Cdc37, 
while Cdc37 also interacts with Hsp70 through its Bag-like motif.  Cdc37 then stimulates 
Hsp70 to release the client kinase, while Cdc37’s D2a domain activates the nucleotide 
mediated conformational switching of Hsp90 and subsequent client kinase binding by 
Cdc37’s KBD.  “Late complex” co-chaperones, such as p23 and PP5 then bind to the 
dimerized Hsp90 chaperone complex and help facilitate the folding of the client kinase. 
 
Hsp90 Client Binding Mechanisms 
 The findings in this report indicate that Hsp90 interacts with kinases and possibly 
other clients at two different sites. These findings combined with the possibility that 
Hsp90 may have more than one client binding interface or client binding motif (CBM) 
suggests a relatively novel Hsp90 mechanism of action.  The NAD and MD have both 
been shown to have some form of client binding activity indicating that each one 
possesses a binding interface. Besides having binding interfaces, these domains also 
contain most of the residues needed for Hsp90 ATPase activity.   The NAD contains the 
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ATP binding pocket, and the MD possesses several critical residues needed for ATP 
hydrolysis [R380 and Q384 in yeast] (54).  However, these catalytic residues, like the 
binding interfaces, are separated by the evolutionarily variable and extremely flexible 
LD.  The organization of Hsp90’s structure suggests that in order for Hsp90 to hydrolyze 
ATP when it is in the ATP-bound or “slow on/slow off” conformation, it must bring the 
NAD and MD together, which in turn would bring the binding interfaces together.  The 
approximated binding interfaces could then synergistically bind the client in a number of 
ways (Fig. 28): (i) combining the binding interfaces to create one large interface; (ii) 
“sandwiching” one region of the client between the two binding interfaces; or (iii) each 
binding interface recognizing a different site on the client before the domains are brought 
together upon ATP binding.  The latter mechanism is the most favored as it truly utilizes 
both client sites and suggests that Hsp90 folds extended and unstable clients by bringing 
together their different domains.  The CD has also been shown to possess client binding 
activity but was not fully considered when developing this simple model due to the 
complexity that may entail. 
 Additionally, two possibilities exist for the approximated orientation of the NAD 
and MD (Fig. 29): (i) the two domains interact in an intra-molecular manner or within the 
same Hsp90 subunit; or (ii) the two domains interact in an intermolecular manner with 
the NAD of one Hsp90 subunit interacting with MD of the other (suggested by Harris and 
co-workers, unpublished).  Again, the latter mechanism is favored because it takes full 
advantage of the need for Hsp90 to dimerize for ATP hydrolysis to occur.  Each model 
must also take into account that both Hsp90 monomers must place their NAD 
dimerization motifs (NDM) next to each other upon ATP binding and p23 association.  
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Fig. 28. Models of Hsp90’s dual client binding mechanism. The black circles represent 
the client binding motifs (CBM) while all other Hsp90 domains are labeled and colored 
according to Fig.2.  The light blue rectangle represents the client protein with each X 
indicating a possible Hsp90 binding site. (A) One or the other CBM weakly binds the 
client while in the open or ADP-bound conformation. Upon ATP-binding, the CBMs 
come together to form an enhanced CBM surface that strongly binds the client or 
provides a folding surface for clients to template off of. (B) Again, one or the other CBM 
weakly binds the client while in the open or ADP-bound conformation. Upon ATP 
binding, the CBMs come together to “sandwich” the client in a hydrophobic embrace. 
(C) Each CBM binds weakly to different binding sites on the client while in the ADP-
bound conformation. Upon ATP binding, the CBMs come together bringing the client’s 
binding sites along with them, in order to compress, collapse, and fold the client protein. 
Additional models that combine any of the three described models are also possible. 
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Fig. 29.  Model of Hsp90 dimerization.  The teal and cyan ovals represent the NAD 
dimerization motifs (NDM) while all other Hsp90 domains are labeled and colored 
according to Fig.2. and Fig. 28.  In both models Hsp90 starts out in the ADP-bound 
incompletely dimerized conformation.  Upon ATP-binding the NADs come together and 
the NDMs associate. While at the same time the NAD and MD come close, bringing 
together the CBMs. (A) The NADs and MDs and therefore the CBMs associate intra-
molecularly. (B) One NAD associates with the other monomer’s MD and vice versa, 
making the CBMs associate intermolecularly. 
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This overall mechanism would also require that the LD remain flexible, as the inability to 
do so would result in some form of inhibition of Hsp90’s function.  Coincidentally, all 
known post-translational modifications of Hsp90 have been mapped to the LD (56), long 
hinting that it is a major site of Hsp90 regulation. 
 
Protein Kinase Evolution 
 The role of Hsp90 and Cdc37 in protein kinase folding appears to be the 
stabilization of structural motifs in protein kinases that have become exposed or unstable.  
These structural motifs are not defined by amino acid sequence and currently cannot be 
defined by any specific secondary or tertiary structure.  This ambiguity, however difficult 
it makes the study of these interactions, suggests a vast amount versatility and 
functionality in the ability of Hsp90 and Cdc37 to chaperone their clients.   
 Alterations of flexible hinges or other functional motifs in kinases can induce or 
reduce chaperone association.  As one would expect, point mutations that disrupt and 
destabilize the kinase structure, cause an increase in Hsp90 and Cdc37 association.  Yet, 
the residues in these motifs do not necessarily define the area of Hsp90 or Cdc37 
interaction, but instead may indicate the motif is required to stabilize another structural 
feature that is recognized by Hsp90 or Cdc37.  Furthermore, the affinity of Hsp90 and 
Cdc37 for structurally unstable kinases may be by design, as some inherently unstable 
kinases only function with the aid of Hsp90 and Cdc37.  This dependence on Hsp90 and 
Cdc37 is observed with the kinases v-Src and ErbB2 (148, 171), which rely on 
continuous chaperone association for their kinase activity and cellular stability.  This 
continuous dependence on Hsp90 and Cdc37 has even developed into a form of 
 120
regulation for ErbB2 (171).  Thus, given the assistance of Hsp90 and Cdc37, certain 
alterations that weaken the structural stability of kinases may be tolerated within the cell.   
 This assistance may have allowed protein kinases to evolve into the signaling 
proteins required for the viability of countless organisms.  The crystal structure of the 
Archaeoglobus fulgidus kinase, Rio2 hints at this possibility (202).  Evolutionarily 
conserved, a wide variety of homologs of Rio2 have been identified from Archaea to 
humans. Though its exact mode of action is not clear, Rio2 has been found to be required 
for rRNA processing in yeast (203).  The structure of Rio2, described as atypical, is 
similar to most protein kinases except it does not have a truly complete CL and it has a 
winged helix domain sitting directly on top of the NL. The incomplete CL does not 
contain an APE box motif or structural motifs VIII-XI, but instead contains two alpha-
helices following the DFG-like motif in subdomain VII.  This suggests that Rio2 does not 
have a discernible substrate binding motif, activation loop, or most of the structural 
features found in the CL of typical kinases.  What Rio2 does have is the minimum kinase 
structure shown by us to be required for Hsp90 association (163) (Fig. 30), this being the 
NL through subdomain VIB according to our findings.  These features suggests that 
Hsp90 may have evolved to recognize the minimum structural features required for 
kinase activity since these subdomains most likely have always been present throughout 
kinase evolution.  On the other hand, this might also suggest that kinases were allowed to 
evolve because their minimal structure was recognized by Hsp90.   
 The intimate interactions of the NL and the preceding winged helix domain of 
Rio2 indicates that Cdc37 would not be needed to provide stability while folding.  
Similar in function to the anti-parallel β-sheets of the NSD in MAPK/SAPKs, the  
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Fig. 30.  Strucural comparison of atypical and typical protein kinases.  Each kinase is shown 
with its ATP-binding cleft facing away from the viewer. N-terminal non-catalyic regions are 
shown in yellow. The defined Hsp90 and Cdc37 binding domain according to Prince and Matts 
(163) is shown in blue. The remaining CL structure is shown in red. (A) Rio2 (PDB: 1TQP ) (B) 
ChaK (PDB: 1IA9) (C) APH(3’)-IIIa (PDB: 1L8T) (D) Cdk2 (PDB: 1FIN ) 
 
A B
C D 
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winged helix domain instead places an α-helix directly on top of the five β-sheets of the 
NL to stabilize the structure, thus suggesting that the KBD of Cdc37 may instead utilize 
an alpha helix structure to stabilize the NL of kinases.   
 Additionally, although the structure of the NL of Rio2 is similar to typical kinases 
the truncated CL resembles the corresponding lobe of metabolic enzymes with the ATP-
grasp fold.  This is also found in another atypical kinase referred to as ChaK (204).  This 
feature indicates, as suggested by Grishin, that protein kinases evolved from metabolic 
enzymes (205).  This hypothesis is further strengthened by the crystal structure of 
APH(3’)-IIIa; a kinase produced by pathogenic Gram-positive bacteria that confers broad 
antibiotic resistance by phosphorylating a variety of aminoglycosides (206).  An activity 
most likely developed from the production of primary or secondary metabolites.  The 
overall structure of APH(3’)-IIIa is similar to Rio2 in that it has a preceding α-helix that 
layers on top of theβ -sheet structure of the NL.  The rest of the NL structure resembles a 
typical protein kinase, while the CL similar to Rio2 and ChaK diverges after the capping 
of the αE-helix.  Possibly reinforcing our findings, that this is the minimal structure 
needed to be recognized by Hsp90.    
 The evolution from single cell prokaryotes to multi-cellular eukaryotes in many 
instances may be dependent on groups of cells being able to communicate with each 
other. Protein kinase networks along with their receptors are in many ways designed for 
this communication.  It therefore can be speculated that this ability to communicate may 
have started with APH(3’)-IIIa-like proteins phosphorylating random metabolites which 
eventually evolved into protein kinases specifically adding phosphate groups to other 
proteins, in order to alter their function.  It then could be further speculated, that the 
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ability of Hsp90 to maintain the function of these signaling proteins would indicate that 
Hsp90 and its homologues have played a major role in kinase evolution, and giving 
further support to the speculation of Lindquist and co-workers that Hsp90 is a vital 
vehicle for evolution at both the molecular and phenotypic level (16, 19).   
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